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Abstract 
Chimeric Antigen Receptor (CAR) T cell therapies for hematologic malignancies have been astonishingly 
successful in driving cancer remissions. However, early loss of CAR T cells and return of normal B cells is 
a predictor of relapse in pediatric acute lymphoblastic leukemia; the duration of remission is associated 
with the persistence of CAR T cells for more than three months. These CAR T cells are the product of over 
30 years of research and innovation in T cell biology and engineering, which began with the desire to 
understand how the T cell receptor (TCR) activates T cells in response to antigen. In this thesis, we return 
to that approach again, but this time to investigate signaling downstream of the costimulatory receptor, 
4-1BB, a TNF Receptor Superfamily (TNFRSF) member. 4-1BB-costimulated CAR (BBz) T cells exhibit 
longer persistence following adoptive transfer than CD28-costimulated CAR (28z) T cells, which contain 
the first costimulatory domain commonly added to CARs. 4-1BB signaling improves T cell persistence 
even in the context of 28z CAR activation, which indicates that the 4-1BB cytoplasmic domain contributes 
unique pro-survival signals. In order to specifically study CAR signaling, we developed a cell-free ligand-
based activation and ex vivo culture system for CD19-specific CAR T cells. In this system, we observed 
greater ex vivo expansion and survival of BBz CAR T cells compared to 28z T cells. We used this system 
to isolate a pathway activated most by BBz CARs, the non-canonical NF-kB (ncNF-kB) pathway, which is 
associated with the survival benefit from imparted by other TNFRSFs. We observed that BBz CARs 
uniquely activate non-canonical NF-kB (ncNF- kB) signaling in T cells basally, and the anti-CD19 BBz CAR 
further enhances ncNF-kB signaling following ligand engagement. Reducing ncNF-kB signaling 
specifically diminishes anti-CD19 BBz T cell expansion and survival and is associated with a significant 
increase in expression of the most pro-apoptotic isoforms of Bim. Although our findings do not exclude 
the importance of other signaling differences between these CARs, they demonstrate the necessary and 
non-redundant role of ncNF-kB signaling in promoting BBz CAR T cell survival that likely underlies the 
engraftment persistence observed with this CAR design. 
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ABSTRACT 
FROM BENCH TO BEDSIDE AND BACK AGAIN: CAR T CELL SIGNALING AND 
SURVIVAL 
Benjamin Philipson 
Michael Milone 
Chimeric Antigen Receptor (CAR) T cell therapies for hematologic malignancies 
have been astonishingly successful in driving cancer remissions. However, early loss of 
CAR T cells and return of normal B cells is a predictor of relapse in pediatric acute 
lymphoblastic leukemia; the duration of remission is associated with the persistence of 
CAR T cells for more than three months. These CAR T cells are the product of over 30 
years of research and innovation in T cell biology and engineering, which began with the 
desire to understand how the T cell receptor (TCR) activates T cells in response to 
antigen. In this thesis, we return to that approach again, but this time to investigate 
signaling downstream of the costimulatory receptor, 4-1BB, a TNF Receptor Superfamily 
(TNFRSF) member. 4-1BB-costimulated CAR (BBz) T cells exhibit longer persistence 
following adoptive transfer than CD28-costimulated CAR (28z) T cells, which contain 
the first costimulatory domain commonly added to CARs.  4-1BB signaling improves T 
cell persistence even in the context of 28z CAR activation, which indicates that the 4-
1BB cytoplasmic domain contributes unique pro-survival signals. In order to specifically 
study CAR signaling, we developed a cell-free ligand-based activation and ex vivo 
culture system for CD19-specific CAR T cells. In this system, we observed greater ex 
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vivo expansion and survival of BBz CAR T cells compared to 28z T cells. We used this 
system to isolate a pathway activated most by BBz CARs, the non-canonical NF-kB 
(ncNF-kB) pathway, which is associated with the survival benefit from imparted by other 
TNFRSFs. We observed that BBz CARs uniquely activate non-canonical NF-kB (ncNF-
kB) signaling in T cells basally, and the anti-CD19 BBz CAR further enhances ncNF-kB 
signaling following ligand engagement. Reducing ncNF-kB signaling specifically 
diminishes anti-CD19 BBz T cell expansion and survival and is associated with a 
significant increase in expression of the most pro-apoptotic isoforms of Bim. Although 
our findings do not exclude the importance of other signaling differences between these 
CARs, they demonstrate the necessary and non-redundant role of ncNF-kB signaling in 
promoting BBz CAR T cell survival that likely underlies the engraftment persistence 
observed with this CAR design. 
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CHAPTER 1 – INTRODUCTION 
 Chimeric Antigen Receptor (CAR) T cell therapies for resistant acute 
lymphoblastic leukemia in children and young adults have been astonishingly successful 
in driving cancer remissions. However, the duration of remission is associated with the 
persistence of CAR T cells for more than three months; early loss of T cell persistence 
and return of normal B cells is a predictor of relapse (Majzner and Mackall, 2019; Maude 
et al., 2014). These persistent CAR T cells are the product of over 30 years of research 
and innovation in T cell biology and engineering, which, in a way, began with the simple 
desire to understand how the T cell receptor (TCR) activates T cells in response to an 
antigen (Kuwana et al., 1987). At the same time, physician-scientists were attempting to 
harness T cells to treat melanoma patients, but struggled to direct these cells against the 
patients’ tumors specifically (Rosenberg et al., 1988). T cells genetically engineered to 
express CARs could be specifically directed to activate upon encountering cells coated 
with or expressing antigens bound by the CAR, which triggered the CAR T cells to kill 
these “targets” and produce pro-inflammatory signals (Hege and Roberts, 1996). 
However, these “first generation” CAR T cells generally performed poorly in animal 
models and clinical trials. First generation CARs were unable to initiate or sustain enough 
T cell activation to produce an effective therapy, and instead made the CAR T cells 
anergic (Brocker and Karjalainen, 1995; Majzner and Mackall, 2019). Just as these initial 
in vivo studies failed, immunologists discovered that T cells required a second signal to 
the one provided by the TCR to fully activate T cells and promote optimal clonal 
proliferation (Smith-Garvin et al., 2009). This second signal, termed “costimulation”, 
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could be provided by a number of different molecules. As such, a series of “second 
generation” CARs were constructed, which incorporated the intracellular domain of 
different costimulatory receptors with the z-chain of the TCR that had been used in first 
generation CARs (van der Stegen et al., 2015). Second generation CAR T cells with 
CD28 or 4-1BB costimulatory domains targeting B cell leukemias succeeded where their 
first generation progenitors had failed: first in animal models (Brentjens et al., 2007; Imai 
et al., 2004; Kochenderfer et al., 2009; Kowolik et al., 2006; Milone et al., 2009) and then 
in the clinic (Ramos et al., 2014). However, sustained remissions in pediatric ALL are 
more frequently achieved by 4-1BB-costimulated CAR T cells that remained detectable 
in patients for over 3 months (Majzner and Mackall, 2019). In this thesis, we investigate 
how the signaling initiated by 4-1BB costimulation enhances CAR T cell survival. 
ORIGIN OF CARs 
Chimeric antigen receptors, or CARs, are fusion proteins, combining components 
of multiple other proteins into a single structure that can bind to a target and activate the 
cell in which the CAR is expressed. CARs were initially built to investigate how the T 
cell receptor (TCR) upon recognizing its target, known as its antigen, activates a T cell. 
The first such investigation was published in 1987 by Yoshikazu Kurosawa and 
colleagues at the Institute for Comprehensive Medical Science at Fujita-Gakuen Health 
University in Aichi, Japan (Kuwana et al., 1987). At the time, it was already understood 
that the TCR only recognized its antigen and triggered T cell activation when that antigen 
was presented to it by another protein, the major histocompatibility complex (MHC), on 
the surface of an adjacent cell (Schwartz, 1985). This antigen-MHC presentation 
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requirement of the TCR contrasted with how the other component of the adaptive 
immune system, the B cell-generated antibody, bound to its antigen without need of other 
proteins in spite of structural similarities between it and the TCR (Hedrick et al., 1984). 
Kurosawa and colleagues investigated whether a TCR directed to bind an antigen 
in the absence of the presentation could activate a T cell. To do so, they created a 
blended, or chimeric, antigen receptor by attaching the heavy or light chains of an 
antibody targeting phosphorylcholine to the transmembrane and intracellular domains of 
the TCR alpha or beta chains (Kuwana et al., 1987). These two TCR chains do not 
contain the intracellular domains, known as immunoreceptor tyrosine-based activation 
motifs (ITAMs), to activate the T cell, but must associate with the other TCR chains that 
do contain ITAMs to achieve T cell activation. Using a T cell line transfected with 
combinations of the chimeras that each contained both heavy and light chains, Kurosawa 
and colleagues observed that bacteria coated in phosphorylcholine, but not with bacteria 
lacking phosphorylcholine, activated the T cells (Kuwana et al., 1987). This observation, 
and a similar one of digoxin-targeted CARs activating T cells shortly thereafter (Becker 
et al., 1989), demonstrated that these CARs could activate T cells in an antigen-specific 
manner, and therefore functionally associate with the other chains of the TCR. 
These first CARs were successful in demonstrating that the TCR needs only to be 
bound to its target to achieve T cell activation. They also illustrated that T cells not only 
responded to the antigens for which their TCRs had been selected during their maturation 
process, but could also be directed to respond to an additional antigen of choice. This 
second utility was quickly coopted by Zelig Eshhar and his colleagues at the Weizmann 
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Institute in Rehovot, Israel to overcome a challenge encountered by Steven Rosenberg 
and his colleagues at the National Cancer Institute in attempting to harness immune cells 
to treat cancer (Eshhar et al., 1993; Gross et al., 1989): Finding and growing enough T 
cells that activate when exposed to tumor cells to treat patients was nearly impossible for 
most cases (Rosenberg et al., 1988; 1985; Topalian et al., 1987). However, when these T 
cells were found, their activation resulted in them killing the tumor cells to which they 
were reacting (Hellstrom et al., 1968; Hellström et al., 1968; Lotze et al., 1981), and 
causing durable remissions in a small number of patients with melanoma (Rosenberg et 
al., 2011). Yet, just the observation that human T cells could kill tumor cells was wildly 
controversial. 
TREATING CANCER USING THE IMMUNE SYSTEM 
The motivating idea behind CAR T cell therapy, that the human immune system 
fights cancer, seems both relatively new and yet fully accepted, but dates back at least as 
far back as the 1890s and only began to gain acceptance in the 1980s. William Coley, a 
New York surgeon in the 1890s, noticed anecdotally that patients who developed 
transient infections after having tumors removed were more likely remain cancer-free. He 
attempted to apply this observation by injecting the area around tumors he had removed 
initially with live and then with heat-killed bacteria. Although there is little evidence that 
his technique at the time worked, the idea stuck. The observation in 1917 by J.C. 
Mottram and Sidney Russ that rats are capable of rejecting rat sarcoma tumors provided 
some of the earliest published evidence of immune-mediated rejection of a tumor (J C 
Mottram and Sidney Russ, 1917), and attempts to immunize patients to their own tumor, 
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removed, irradiated and reinjected, occurred as early as 1922 (Kellock et al., 1922). 
Nevertheless, a review was published seven years later, now quoted repeatedly, stating 
“It would be as difficult to reject the right ear and leave the left ear intact as it is to 
immunize against cancer.” (Rosenberg, 1999; Woglom, 1929). 
Ultimately, research on bone marrow transplants would provide the strongest 
evidence that human immune cells were capable of driving cancer into remission. Bone 
marrow transplantation initially seemed to solve a problem created by what became a 
leading treatment for blood cancers: myeloablative chemotherapy. Doctors attempted to 
treat blood cancers using so much chemotherapy that the patient’s own hematopoietic 
stem cells, responsible for creating their immune cells and red blood cells, died. To 
rescue the patient from bone marrow failure, physicians transplanted healthy bone 
marrow from a donor to replace the marrow that had been destroyed by the 
chemotherapy. This strategy was validated by early studies of bone marrow 
transplantation in mice that demonstrated that bone marrow from a genetically identical 
mouse could be used to repopulate the full repertoire of cells of the blood (Barnes et al., 
1956). Intriguingly, marrow from donor mice that was exposed to a tumor and then 
transplanted into recipient mice was more successful in maintaining the recipient mice 
cancer-free than marrow from an unexposed donor (Barnes and Loutit, 1957). Yet, nearly 
twenty years later, an analysis of allogeneic bone marrow transplantation in 1975 
concluded that “the data on allogeneic marrow transplantation for hematologic neoplasia 
permit no conclusion about the existence or absence of an antileukemic effect of graft-
versus-host disease…” (Thomas et al., 1975). The therapeutic failure of marrow depleted 
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of T cells to prevent a potentially deadly side-effect of bone marrow transplants attacking 
the recipient, graft-versus-host disease, firmly demonstrated that successful bone marrow 
cancer treatment required T cells (Goldman et al., 1988). 
DEVELOPING CAR T CELL THERAPIES FOR CANCER 
 Returning to Rosenberg’s challenge, Eshhar and his colleagues rapidly developed 
a set of CARs to direct T cells to kill tumor cells in vitro. T cells were first targeted to 
antigens coated onto tumors using CARs comprised of two separate molecules, the TCR 
a and b chains each fused to the heavy or light chain of an antibody variable region 
(Gross et al., 1989). CARs were then combined into a single molecule by two different 
groups, who both fused the extracellular domains of T cell co-receptors to the 
transmembrane and intracellular domains of ITAM-containing immunoreceptors, the 
CD3z chain (Irving and Weiss, 1991; Romeo and Seed, 1991), or the Fcg chain (Romeo 
and Seed, 1991). To maintain the single-chain structure but retain the targeting 
demonstrated by the combined heavy and light chain antibody fragment approach, the 
heavy and light chains were connected by a linker, creating a single-chain variable 
fragment (scFv). This scFv was then fused to either the z- or g-chain to create the first 
single molecule CAR targeting cancer cells coated with an antigen (Eshhar et al., 1993). 
Eshhar and his team would go on to publish not one, but two functional “first generation” 
CARs directed towards two different antigens expressed natively on the tumor cells, the 
alpha-folate receptor and Her2 [ERBB2] (Hwu et al., 1993; Stancovski et al., 1993). Yet, 
as effective as these early CAR T cells were at killing tumor cells in vitro, these results 
were not readily recapitulated in animal models. 
7 
 
 The next step in translating what started as a laboratory tool to a cancer therapy 
was to use these “first generation” CAR T cells to eradicate tumors in mice. 
Unfortunately, multiple groups found that their success in vitro did not lead to tumor 
clearance in vivo (Hwu et al., 1995; Moritz et al., 1994). These early failures in mouse 
models with “first generation” CARs would ultimately prove predictive of human clinical 
trials (Deeks et al., 2002; Kershaw et al., 2006; Park et al., 2007; Till et al., 2008) despite 
contradictory evidence from a report using a z-chain CAR targeting ERBB2 in a mouse 
breast cancer model (Altenschmidt et al., 1997), and another demonstrating that a z-chain 
CAR was superior to a g-chain CAR in a colon cancer model (Haynes et al., 2001). One 
possible explanation for these failures was a z-chain CAR alone was inadequate to 
activate T cells without those T cells having been previously activated (Brocker and 
Karjalainen, 1995), like the TCR from which the CAR signaling domain was derived 
(Harding et al., 1992; Tan et al., 1993). 
SECOND GENERATION CARs: ADDING COSTIMULATION 
 The missing ingredient to achieve T cell activation was costimulation. Initially, 
costimulation was found to be provided to previously unstimulated T cells by the 
immunoglobulin superfamily member, CD28 (Harding et al., 1992; June et al., 1987; Tan 
et al., 1993). When CD28 bound to its ligands, CD80 or CD86, in the absence of TCR 
activation, T cells did not activate. However, simultaneous TCR and CD28 ligand 
binding drove robust T cell activation. Because CD28 ligand binding had no effect on its 
own, this cooperative phenomenon was called “costimulation.” 
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To incorporate costimulation into CARs, CD28 was combined with activation 
from an ITAM-containing receptor in T cells initially as two separate molecules: an scFv 
fused to the transmembrane and intracellular domains of CD28 (Krause et al., 1998) 
alone, or co-expressed with a z-chain CAR (Alvarez-Vallina and Hawkins, 1996). The 
first single molecule with CD28, the z-chain, and a single scFv targeted CD33, a protein 
expressed on acute myeloid leukemia cells, and only demonstrated an improvement over 
the z-chain-only CAR in IL-2 secretion, the growth factor that Rosenberg had used to 
expand the tumor-reactive T cells from his melanoma patients (Finney et al., 1998). Yet, 
this single reported enhancement triggered a new race to build costimulated “second 
generation” CARs that would succeed where “first generation” CARs had failed, in vivo. 
 Most groups constructed CARs that employed the CD28 costimulatory domain in 
a second-generation design and targeted antigens on solid tumors (Hombach et al., 2001; 
Maher et al., 2002; van der Stegen et al., 2015). Bucking both trends and drawing upon 
the lessons of bone marrow transplant for treating leukemia, Michael Jensen’s group at 
the City of Hope Medical Center and the Fred Hutchinson Cancer Research Center 
postulated that directing T cells specifically to leukemia cells would be a potent 
technique, but would spare the patient the toxicities of graft-versus-host-disease (Cooper 
et al., 2003). Jensen and colleagues created a “first generation” CAR targeted to CD19, a 
universal B cell marker and one present on nearly all leukemia cells originating from B 
cells (Cooper et al., 2003). These human anti-CD19 CAR T cells efficiently killed CD19-
expressing leukemia cells in culture. As was the case with all previous “first generation” 
CARs, this CAR would be replaced with more effective “second generation” CARs 
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(Brentjens et al., 2007; Imai et al., 2004; Kochenderfer et al., 2009; Kowolik et al., 2006; 
Milone et al., 2009). 
 Unlike the initial trend in “second generation” CAR development, two of these 
groups incorporated 4-1BB, a Tumor Necrosis Factor Receptor Superfamily (TNFRSF) 
member, instead of CD28 in their anti-CD19 CARs (Imai et al., 2004; Milone et al., 
2009). 4-1BB can substitute for CD28 costimulation in T cells (DeBenedette et al., 1997; 
Saoulli et al., 1998), limit T cell death from activation (Hernandez-Chacon et al., 2011) 
and was found to be critical for cytotoxic T cell memory (Wang et al., 2009). Dario 
Campana and his team at the St. Jude Children’s Research Hospital in Memphis, 
Tennessee, demonstrated that a CD19-specific CAR constructed with the 4-1BB 
cytoplasmic domain were better killers of leukemia cell blasts than those without 4-1BB 
(Imai et al., 2004). The group of investigators lead by Carl June at the University of 
Pennsylvania incorporated this CAR into an optimized lentiviral vector transduction 
system and combined it with a well-established microbead-based human T cell 
manufacturing platform developed in HIV-targeted CAR T cell trials (Levine et al., 1998) 
born out of the early work done to combine the CD4 coreceptor with the z-chain (Romeo 
and Seed, 1991). This work demonstrated that manufactured human anti-CD19 4-1BB 
costimulated CAR-T cells are more effective than their CD28-costimulated counterparts 
in immunocompromised mouse models of human primary acute lymphoblastic leukemia 
(Milone et al., 2009). Armed with this improved “second generation” CAR, the anti-
CD19 4-1BB CAR-T cell therapy was launched into the clinic. 
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Fighting the fading, but still impactful skepticism regarding cancer 
immunotherapy, the June group published the results of a small pilot trial using anti-
CD19 4-1BB costimulated CAR T cell therapy to treat three patients with the chronic 
lymphocytic leukemia (Porter et al., 2011). Surpassing all expectations, all three patients 
experienced complete remissions. This first success was followed by an expanding 
cascade of trials using either CD28 or 4-1BB costimulated anti-CD19 CAR T cells to 
treat B cell leukemias (Maude et al., 2018; Neelapu et al., 2017; Ramos et al., 2014), 
which resulted in the first FDA approvals of CAR T cell therapies for CD19-positive B 
cell malignancies: first for 4-1BB costimulated CAR T cell treatment of pediatric and 
young adult ALL (O'Leary et al., 2019), and then for CD28 costimualted CAR T cell 
treatment of adult diffuse large B cell lymphoma (Bouchkouj et al., 2019). From these 
trials, specifically those in pediatric and young adult ALL, an important pair of patterns 
emerged: Durable remissions were sustained when CAR T cells persisted for many 
months in patients (Mueller et al., 2018), and the most persistent CAR T cells were those 
with 4-1BB costimulation (Majzner and Mackall, 2019). 
However, comparing the results of these trials is difficult as there are multiple 
differences between the CAR T cells used in these trials, including different antibody 
single-chain variable fragments, vector backbones used to transduce the T cells with 
CAR DNA, and culture methods to expand the CAR T cells prior to treatment (Barrett et 
al., 2014; Maude and Barrett, 2016; Miller and Rosman, 1989; Naldini et al., 1996). Two 
preclinical studies directly comparing CD28 and 4-1BB costimulated CARs, one using 
retroviral transduction (Long et al., 2015) and the other using lentiviral transduction 
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(Wang et al., 2015), both showed that 4-1BB costimulated CAR T cells persist longer 
than their CD28 costimulated counterparts. To compare the impact of CAR-mediated 
CD28 and 4-1BB costimulation on CAR T cell proliferation and survival in the absence 
of initial T cell receptor and CD28 stimulation, our group used RNA electroporation to 
transiently express anti-CD19 z-chain-based CARs with either CD28 or 4-1BB 
costimulatory domains in human T cells and stimulated these T cells with CD19 target 
beads (Kawalekar et al., 2016). Our group found that 4-1BB costimulated RNA CAR T 
cells proliferated and survived longer in vitro than their CD28 costimulated counterparts. 
In addition, more 4-1BB costimulated RNA CAR T cells expressed surface markers of T 
cell memory and had greater spare respiratory capacity, mitochondrial mass, and higher 
levels of the master regulator of mitochondrial biogenesis, TFAM than their CD28 
costimulated counterparts (Kawalekar et al., 2016). This additional spare respiratory 
capacity likely underlies the proliferative and persistence advantage of memory T cells 
over effector T cells used in a murine model of adoptive T cell cancer therapy (van der 
Windt et al., 2013). These studies identified the CAR costimulatory domain as a key 
determinant of CAR T cell survival, but the mechanisms by which CAR CD28 and 4-
1BB costimulation mediated this effect remained unknown. 
COMPARING CD28 AND 4-1BB SIGNALING 
Most of what is known about these domains comes from studying them in their 
endogenous forms. They are members of two distinct families of receptors; CD28 is a 
member of the immunoglobulin superfamily (Aruffo and Seed, 1987), and 4-1BB 
belongs to the Tumor Necrosis Factor Receptor Superfamily (Smith et al., 1990). CD28 is 
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expressed on quiescent “naive” T cells (Rudd et al., 2009), whereas 4-1BB is only 
expressed on activated T cells (Pollok et al., 1993). They use entirely distinct 
mechanisms to activate downstream signaling. CD28 has a series of motifs that directly 
recruit downstream signaling molecules upon receptor ligation and phosphorylation of 
some of these motifs (Boomer and Green, 2010). In contrast, 4-1BB signals through the 
recruitment of distinct multimers of TNF Receptor Associated Factors (TRAFs) when 
quiescent or upon ligand binding (Zapata et al., 2018). Despite all of these differences, 4-
1BB activation can substitute for CD28 in CD28 KO T cells (DeBenedette et al., 1997). 
As such, one might expect that both receptors signal through largely overlapping 
downstream pathways. 
CD28 signaling is functionally similar to that of the antigen-MHC-bound TCR 
complex. Like the T cell coreceptors, CD4 and CD8, CD28 directly associates with Lck 
(Holdorf et al., 1999; King et al., 1997), which is responsible for phosphorylating the 
tyrosines in the ITAMs of the TCR complex and the activating tyrosines in ZAP-70 (Bu 
et al., 1995; Chan et al., 1995; Pitcher and van Oers, 2003), the pivotal kinase involved in 
transducing ITAM-mediated signaling in T cells (Chan et al., 1992). Upon binding either 
of its ligands, CD80 or CD86, CD28 also functionally mimics LAT, an adaptor recruited 
to the TCR complex, by recruiting PI3K (Pagès et al., 1994; Prasad et al., 1994), which 
drives AKT, mTOR, and canonical NF-kB signaling (Hemmings and Restuccia, 2012), 
and GRB2 (Kim et al., 1998; Schneider et al., 1995), which, through Ras, activates ERK 
and p38 MAPK (Boomer and Green, 2010). Potentiation of these pathways enhances IL-
2 production (Thomas et al., 2005), increases anti-apoptotic protein Bcl-XL expression 
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(Boise et al., 1995), and prolongs T cell survival (Jones et al., 2002). However, 
endogenous CD28 lacks an ITAM, and therefore cannot recruit ZAP-70 or initiate T cell 
activation alone (June et al., 1990). These signaling pathways are depicted in Figure 1.1. 
Upon CD28 activation in conjunction with TCR ligand-binding, CD28 is trafficked away 
from the ITAM-containing subunits of the CD3 complex (Bashour et al., 2014). 
14 
 
Like CD28, 4-1BB must bind its own ligand, 4-1BBL, in the context of TCR 
antigen binding to impact T cell activation (Saoulli et al., 1998). 4-1BB is expressed as 
either a monomer or a dimer upon T cell activation (Pollok et al., 1993) and basally 
associates with TRAFs 2 and 3 (Arch and Thompson, 1998), the latter of which acts as a 
Figure 1.1: TCR and CD28 Signaling Pathways. A Cartoon graphic of an idealized 
interaction between an antigen presenting cell (APC) and a T cell. The TCR complex 
is shown on the right, binding to an antigen-MHCI complex. CD8 is recruited and 
binds the CD3-MHC complex, bringing Lck along with it. Lck phosphorylates ITAMs 
on CD3 (those of CD3z are specifically highlighted here). These phospho-ITAMs 
serve as a binding site for ZAP-70, which is also phosphorylated by Lck. CD28, on 
the right, engages its ligand, CD80. This interaction triggers phosphorylation of its 
membrane-proximal YMNM-motif, which recruits PI3K and GRB2. These two 
molecules then activate downstream signaling, of which mTOR, canonical NF-kB, 
ERK and p38 MAPK are highlighted here. Those downstream signals of interest 
shared with 4-1BB are highlighted. 
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negative regulator (Takaori-Kondo et al., 2000). Upon trimerization by binding 4-1BBL 
(Bitra et al., 2018; Gilbreth et al., 2018a; Won et al., 2010), 4-1BB recruits TRAF1 (Arch 
and Thompson, 1998), and together with TRAF2, induces ubiquitin-mediated degradation 
of TRAF3 (Jang et al., 1998; McPherson et al., 2012). TRAF3 degradation combined 
with TRAF1 recruitment causes the initiation of downstream signaling by ERK activation 
(Sabbagh et al., 2008) through LSP1 (Sabbagh et al., 2013), canonical NF-kB signaling 
(Arch and Thompson, 1998) through TBK1 phosphorylation of IKKa/b (Oussa et al., 
2013), and p38 MAPK through ASK1 (Cannons et al., 2000; Menk et al., 2018) (Figure 
1.2). Though the intermediates are different, endogenous 4-1BB signaling largely appears 
to overlap with signaling driven by CD28. 
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Studies exploring CAR costimulatory domain signaling have been somewhat 
limited, but have generally recapitulated this overlap. The broadest comparison between 
anti-CD19 CD28 and 4-1BB costimulated CAR signaling was recently published by 
Stanley Riddell and his colleagues at the Fred Hutchison Cancer Research Center in 
Seattle, WA (Salter et al., 2018). Using activated T cells expressing anti-CD19 CD28 or 
4-1BB costimulated CARs and beads coated with antibodies against an ST2 tag within 
Figure 1.2: TCR and 4-1BB Signaling Pathways. A Cartoon graphic of an idealized 
interaction between an activated antigen presenting cell (APC) and an activated T cell. 
The TCR complex is shown on the right, as in Figure 1.1. 4-1BB, on the right, 
engages its ligand, 4-1BBL. This interaction triggers trimerization and recruitment of 
TRAFs 1 and 2, which induce the degradation of the negative regulator, TRAF3. 
TRAFs 1 and 2 then activate downstream signaling, of which ERK, canonical NF-kB, 
and p38 MAPK are highlighted here. Those downstream signals of interest shared 
with CD28 are highlighted. 
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the CARs, these investigators assessed phosphorylation of numerous proteins by mass 
spectrometry 15 minutes and 45 minutes after CAR activation. This unbiased approach 
confirmed the overlap in phosphorylation targets between the CD28 and 4-1BB 
costimulated CARs, but also revealed that the CD28 CAR drives greater phosphorylation 
of these targets in this timeframe. These findings may partially explain how CD28 
costimulated CAR T cells become more glycolytic than 4-1BB costimulated CAR T cells 
(Kawalekar et al., 2016), as this is a feature of CD28 costimulation (Frauwirth et al., 
2002). They may also explain why limiting the ITAMs on the CAR z-chain improves 
CAR T cell survival (Feucht et al., 2019), as this strategy may mimic the diminished the 
downstream signaling of the 4-1BB costimulated CAR. However, if this kinetic and 
quantitative signaling difference were the only one between these costimulatory domains, 
adding 4-1BB costimulation to that provided by CD28 should be lost in the noise of the 
CD28 signal. Yet, when CD28 CAR T cells are costimulated separately by 4-1BB, such 
as by 4-1BBL expression to activate endogenous 4-1BB, those CAR T cells have 
enhanced survival and persistence (Drent et al., 2019; Zhao et al., 2015).   
The major hypothesis of my thesis is that the enhanced persistence observed 
with 4-1BB-costimulated CAR T cells is supported by induction of the non-
canonical NF-kB signaling pathway. This unique NF-kB pathway is activated by 
different TNFRSFs, but not CD28, and is important for promoting cell survival in a 
variety of cell contexts (Coope et al., 2002; Hauer et al., 2005; Li et al., 2005; Marinari 
et al., 2004; Müller and Siebenlist, 2003; Sun, 2017). 
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Nuclear Factor k-light-chain-enhancer of activated B cells (NF-kB) signaling is 
sometimes erroneously described as a single pathway that marks active inflammation (Li 
et al., 2018), but is comprised of five different proteins that act as transcription factors by 
combining in various dimer pairs that induce distinct changes in transcription (Figure 1.3) 
(Sun, 2017). RelA, also known as p65, and the active form of p105, p50, form what is 
known as the canonical dimer, and translocate to the nucleus following activating signals 
from a wide variety of stimuli including activation of the TCR (Pitcher and van Oers, 
2003), CD28 (Kane et al., 2002), and 4-1BB (McPherson et al., 2012), along with 
numerous cytokine receptors (Vallabhapurapu and Karin, 2009). Both CD28 and 4-1BB 
costimulated CARs have been reported to activate canonical NF-kB signaling, but these 
reports conflict in the relative importance of canonical NF-kB signaling to the function of 
each CAR (Carpenito et al., 2009; Li et al., 2018). Intriguingly, the CD28 and 4-1BB 
costimulatory domains activate the canonical NF-kB pathway through different proximal 
signaling intermediates. CD28 does so by activating PKCq whereas 4-1BB does so by 
activating TGFb-activated kinase 1. These signals converge to activate the canonical NF-
kB pathway by inducing the Inhibitor of kB kinases (IKKs) a, b, and g, to trimerize and 
phosphorylate Inhibitor of kBs (IkBs), which, when unphosphorylated, bind p65/p50 
dimers and localize them to the cytoplasm. Phosphorylated IkBs are rapidly degraded by 
the proteasome, allowing p65/p50 dimers to translocate to the nucleus and alter gene 
regulation. This activation is often short-lived, as p65/p50 dimers increase transcription 
of IkBs that remove the dimers from the nucleus (Mukherjee et al., 2017; Sun et al., 
1994).  
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Unlike the canonical pathway, the non-canonical NF-kB dimer, RelB/p52, only 
translocates to the nucleus upon activation of certain TNFRSFs and viral proteins and has 
not yet been studied downstream of CAR activation (Sun, 2017). Non-canonical NF-kB 
signaling begins with the stabilization of NF-kB Inducing Kinase (NIK) (Malinin et al., 
1997; Xiao et al., 2001), which TRAF3 basally targets to cIAP1 and 2 (Liao et al., 2004; 
Cytokine
Receptors
CD28
TNFRSFs
Figure 1.3: The canonical (classical) and non-canonical (alternative) NF-kB 
pathways. A Cartoon graphic of multiple surface receptor-mediated pathways to 
initiate canonical or non-canonical NF-kB signaling. The canonical pathway, shown in 
the center, can be activated by a number of receptors (as shown here) and intracellular 
stress signals (not depicted). The canonical pathway converges on the IKKa, b, g 
complex, which phosphorylates IkBs. Phospho-IkBs are degraded, allowing the 
canonical dimer, p65/p50, to enter the nucleus. In contrast, only certain TNFRSFs can 
activate the non-canonical pathway, shown on the right. This pathway is triggered by 
the stabilization of the NF-kB-inducing kinase (NIK), which phosphorylates IKKa. 
IKKa can then phosphorylate p100, creating a phosphodegron. This portion of p100 is 
degraded, leaving the active form, p52, to enter the nucleus in the non-canonical 
dimer, RelB/p52. Adapted from Mortier, J., et al., 2010. 
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Zarnegar et al., 2008). These E3 ubiquitin ligases K48-polyubiqutinate NIK, which is 
subsequently degraded by the proteasome (Zarnegar et al., 2008). Murine 4-1BB-
mediated activation coordinates TRAFs 1 and 2 to shift cIAP1/2-mediated K48 
polyubiquitination from NIK to TRAF3, thereby alleviating NIK K48 polyubiquitination-
mediated degradation (Jang et al., 1998; McPherson et al., 2012; Saoulli et al., 1998; 
Vallabhapurapu et al., 2008; Zarnegar et al., 2008). As NIK slowly accumulates in the 
cytoplasm, it phosphorylates IKKα (Ling et al., 1998) and coordinates a complex 
including IKKα and the NF-kB family member p100 (Xiao et al., 2001). IKKα 
phosphorylates p100 (Senftleben et al., 2001), creating a phosphodegron to be K48-
polyubiquitinated and partially degraded by the proteasome, forming p52 (Xiao et al., 
2001). Prior to NIK and IKKα activation, p100 basally sequesters RelB, another Rel 
homology domain family member, in the cytoplasm. Upon p100 processing to p52, RelB 
and p52 translocate to the nucleus as a heterodimer (Claudio et al., 2002). Therefore, 
p100 processing and RelB/p52 dimer nuclear translocation are the hallmarks of non-
canonical NF-kB activation (Fig. 1.4). 
Both canonical and non-canonical NF-kB signaling drive T cell survival, albeit in 
opposite ways. P65/p50 dimers activate transcription of the Bcl-2 anti-apoptotic protein 
family member, Bcl-xL, which supports survival of both CD28 and 4-1BB costimulated 
T cells (Khoshnan et al., 2000; Stärck et al., 2005). In contrast, RelB/p52 dimers inhibit 
expression of pro-apoptotic proteins Bim and BMF (Vallabhapurapu et al., 2015; Wang 
et al., 2008). Bim and BMF are also members of the Bcl-2 family, but unlike the anti-
apoptotic members of this family, Bim and BMF are part of the BH3-only subfamily 
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(O'Connor et al., 1998). BH3-only Bcl-2 family members promote apoptosis by binding 
anti-apoptotic Bcl-2 family members, thereby preventing them from inhibiting the 
formation of the apoptotic pore on the surface of the mitochondria (Hockings et al., 
2018). Once this pore is opened, cytochrome c escapes from the mitochondrial matrix 
and triggers apoptosis (McArthur et al., 2018) (Figure 1.4). As such, the expression of 
Bim and its fellow BH3-only family members is tightly regulated (Puthalakath and 
Strasser, 2002). Unregulated Bim suppression by constitutive p52 expression causes a 
massive increase in circulating T cells and results in mutli-organ autoimmunty (Wang et 
al., 2008). Conversely, T cells with homozygous inactivating mutations in p100, 
preventing p100 processing to p52, were unable to induce experimental autoimmune 
encephalitis, a T cell-mediated murine autoimmune disease (Yu et al., 2014). 
Furthermore, T cells from NIK knockout mice form few persistent memory cells when 
initially challenged with acute LCMV infection (Rowe et al., 2013). T cell-specific NIK 
knockout mice have substantially fewer circulating memory T cells than WT controls (Li 
et al., 2016). 
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The loss of surviving memory T cells is notable, as T cell phenotype strongly 
impacts T cell antitumor activity (Fraietta et al., 2018; Ghassemi et al., 2018; Klebanoff 
et al., 2005; Sommermeyer et al., 2016). The phenotype of a mature T cell is influenced 
by a number of factors, but generally reflects whether or not that T cell has encountered 
its antigen, and its capacity for future expansion (Gattinoni et al., 2011; Sallusto et al., 
Figure 1.4: Bcl-2 Protein Family Regulation of Innate Apoptosis Pathway. A 
Cartoon graphic of the mitochondrial double membrane depicting the regulation of 
apoptotic pore formation. Anti-apoptotic Bcl-2 family members, represented by the 
green Bcl-xL/Bcl-2, prevent formation of the pore by binding with the pore-forming 
proteins Bax and Bak, shown in red on the right. On the left, Bim, representing BH3-
only proteins, can interfere with the Bcl-xL-Bax interaction by binding Bcl-xL (or 
other Bcl-2 family members) and allow the pore to form. This pore facilitates 
cytochrome c translocation to the cytoplasm, where it initiates apoptosis. 
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2004). Naïve T cells, as their name suggests, are unlikely to have encountered their 
antigen before. They have a high proliferative potential and metabolically favor oxidative 
phosphorylation, but are slow to begin dividing upon activation (Kaech and Ahmed, 
2001). Effector T cells have encountered their antigen and become metabolically 
glycolytic (MacIver et al., 2013). They express proteins enabling them to kill target cells, 
such as granzyme B and perforin, and inflammatory cytokines, but have little to no 
proliferative potential (Sallusto et al., 2004). Finally, memory T cells, and specifically 
stem cell memory T cells, are T cells that have encountered their antigen, but unlike 
effector T cells, have a large proliferative potential, and unlike naïve T cells, can 
proliferate rapidly upon antigen stimulation (Gubser et al., 2013; Sallusto et al., 2004; 
van der Windt et al., 2013). Memory CAR T cells tend to have the greatest antitumor 
efficacy (Ghassemi et al., 2018; Sommermeyer et al., 2016), and the presence of stem cell 
memory T cells in the CAR T cell products made from CLL patients’ T cells correlated 
with long term remission (Fraietta et al., 2018). 
Memory T cells also require oxidative metabolism to develop, function and 
rapidly proliferate (Pearce et al., 2009; van der Windt et al., 2013; 2012). Memory T cells 
basally consume more oxygen to make ATP and have a substantially greater spare 
respiratory capacity, the difference between maximal oxygen consumption elicited by the 
proton ionophore FCCP and basal oxygen consumption, than effector T cells (van der 
Windt et al., 2012). Memory T cell spare respiratory capacity is driven by fatty acid 
oxidation (van der Windt et al., 2012), which, when upregulated, can enhance memory T 
cell proliferation after restimulation (Pearce et al., 2009). Critically, this rapid memory T 
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cell proliferation following restimulation requires substantial mitochondrial mass and 
spare respiratory capacity (van der Windt et al., 2013). Mitochondrial biogenesis and 
spare respiratory capacity have been shown to be increased by activation of the non-
canonical NF-kB pathway in both osteoclasts and skeletal muscle fibers (Bakkar et al., 
2012; Zeng et al., 2015). In both cell types, RelB/p52 dimers were observed to directly 
bind at two sites within the first intron of master mitochondrial biogenesis regulator, pgc-
1b, and increase PGC-1b expression. PGC-1b expression was diminished by RelB 
knockout in the osteoclasts (Zeng et al., 2015) and knockdown in the skeletal muscle 
fibers (Bakkar et al., 2012). Critically, PGC-1b expression correlated with mitochondrial 
mass and oxygen consumption rate in both cell types (Bakkar et al., 2012; Zeng et al., 
2015). The increase in oxygen consumption rate and mitochondrial mass observed in 
these cell types resembles that observed in 4-1BB costimulated CAR T cells (Kawalekar 
et al., 2016). 
Endogenous 4-1BB costimulation also directly promotes T cell persistence 
through the downregulation of Bim (Sabbagh et al., 2008). Bim suppression in T cells by 
4-1BB depends upon ERK activation (Sabbagh et al., 2008). In multiple myeloma cells, 
ERK activation inhibits transcription of the bcl2l11 locus in cooperation with the non-
canonical NF-kB dimer, RelB/p52  (Vallabhapurapu et al., 2015). RelB/p52, together 
with phospho-ERK, binds the bcl2l11 promoter and recruits histone deacetylease 4 
(HDAC4). HDAC4 deacetylates the surrounding histones, thereby closing the locus and 
rendering it inaccessible to RNA polymerases (Vallabhapurapu et al., 2015). When Bim 
is transcribed and translated, it plays a central role in regulating T cell survival through 
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deletion of autoreactive B cell clones (Ludwinski et al., 2009; Wang et al., 2008), and 
short-lived effector T cells (Wojciechowski et al., 2006).  
Given the specific association between TNFRSFs and the non-canonical NF-kB 
pathway, which drives T cell survival, memory T cell-supporting oxidative metabolism, 
and suppression of pro-apoptotic protein, Bim, we hypothesized that 4-1BB-costimulated 
CARs improve T cell survival by induction of oxidative metabolism and suppression of 
Bim by activating the non-canonical NF-kB pathway. 
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CHAPTER 2 
ABSTRACT 
Clinical response to chimeric antigen receptor (CAR) T cell therapy is correlated with 
CAR T cell persistence, especially for CAR T cells targeting CD19+ hematologic 
malignancies. 4-1BB-costimulated CAR (BBz) T cells exhibit longer persistence 
following adoptive transfer than CD28-costimulated CAR (28z) T cells.  4-1BB signaling 
improves T cell persistence even in the context of 28z CAR activation, which indicates 
that the 4-1BB cytoplasmic domain contributes unique pro-survival signals to T cells. In 
order to specifically study the signal transduction by CARs, we developed a cell-free 
ligand-based activation and ex vivo culture system for CD19-specific CAR T cells, in 
which we observed greater ex vivo expansion and survival of BBz CAR T cells when 
compared to 28z T cells. We show that BBz CARs uniquely activate non-canonical NF-
kB (ncNF-kB) signaling in T cells basally, and the anti-CD19 BBz CAR further 
enhances ncNF-kB signaling following ligand engagement. Reducing ncNF-kB signaling 
specifically diminishes anti-CD19 BBz T cell expansion and survival and is associated 
with a significant increase in expression of the most pro-apoptotic isoforms of Bim. 
Although our findings do not exclude the importance of other signaling differences 
between BBz and 28z CARs, they demonstrate the necessary and non-redundant role of 
ncNF-kB signaling in promoting the survival of BBz CAR T cells that likely underlies 
the engraftment persistence observed with this CAR design. 
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INTRODUCTION 
Chimeric antigen receptor (CAR) T cell therapy targeting CD19 has induced 
complete tumor regression in a large percentage of patients suffering from hematologic 
malignancies, especially in children and young adults with acute lymphoblastic leukemia 
(ALL) (Feins et al., 2019). Event-free survival following CD19-specific CAR T cell 
therapy is highly correlated with the kinetics of T cell expansion and the area under the 
concentration-time curve (AUC) for the first 28 days following adoptive transfer 
(Mueller et al., 2018). While antigen or epitope loss remain the most frequent 
mechanisms of resistance to this therapy (Orlando et al., 2018), relapse within the first six 
months is associated with early loss of CAR T cell engraftment illustrating the 
importance of persistent T cell engraftment to the success of adoptive cell therapy 
approaches (Mueller et al., 2018; 2017; Turtle et al., 2016). 
The persistence of CAR T cells in vivo over time following adoptive transfer is 
influenced by CAR design. CARs are transmembrane proteins comprised of an antibody 
single-chain variable fragment (scFv), a hinge connecting to a transmembrane domain, 
and one or more intracellular signaling domains (van der Stegen et al., 2015). The most 
commonly used designs combine the T cell receptor subunit CD3z with the intracellular 
domain of either of the co-stimulatory molecules, CD28 or 4-1BB. Comparing CAR T 
cell persistence across human clinical trials using 28z or BBz CD19-specific CARs, 
although fraught with pitfalls due to the other differences in the CARs used or in T cell 
manufacturing (e.g. scFv, gene transfer vector or culture conditions), suggests greater 
persistence of 4-1BB-costimulated CAR T cell engraftment relative to CD28-
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costimulated CAR T cells (Maude et al., 2018; Neelapu et al., 2017). This trend is more 
directly substantiated in murine adoptive transfer models, implying that costimulation 
directly impacts CAR T cell persistence (Weinkove et al., 2019). When exchanged with 
CD28 costimulation, 4-1BB costimulation also rescues CAR T cell survival in the 
context of a basally signaling CAR (Long et al., 2015), and basally signaling BBz CARs 
can expand dramatically ex vivo (Frigault et al., 2015). 
The signaling pathways that lead to the observed differences in CAR T cell 
persistence remain poorly understood. Salter et al. demonstrated that 28z CARs drives 
both constitutive and CAR-activation-induced proximal signaling through Lck and Zap70 
more potently than the BBz CARs (Salter et al., 2018). This potent proximal signaling 
promotes terminal differentiation of 28z CAR T cells, which can be reversed by silencing 
two of the ITAM domains of the CD3z domain (Feucht et al., 2019). This reversal 
suggests that CD28 signaling in the CAR is a dominant mechanism for this CAR’s 
reduced persistence. However, 4-1BB costimulation enhances CAR T cell survival and 
persistence even in the context of the full 28z CAR signal (Drent et al., 2019; Zhao et al., 
2015). This enhancement is consistent with the non-overlapping roles that these 
costimulatory receptors play in normal immunity, especially for CD8+ T cell memory 
(Bertram et al., 2002; Giardino Torchia et al., 2015; Hurtado et al., 1997; Lee et al., 2002; 
Shuford et al., 1997). Long-term CD8+ T cell survival following viral infections is 
supported by specific Tumor Necrosis Factor Receptor Superfamily members 
(TNFRSFs), including 4-1BB (Hendriks et al., 2005; Snell et al., 2011). Unlike CD28, a 
unique property of these receptors, and specifically observed in one report on murine 4-
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1BB, is the capacity to activate the non-canonical NF-kB pathway (ncNF-kB) (Li et al., 
2005; McPherson et al., 2012; Ramakrishnan et al., 2004; Xiao et al., 2016). Distinct 
from the classical NF-kB downstream of TCR and CD28 signaling via the CARMA1 
complex and PKCq (Kane et al., 2002; Li et al., 2005; Schimmack et al., 2014; Sun et al., 
2000), the ncNF-kB pathway promotes cell survival in numerous contexts including 
normal lymphoid development under the control of TNF receptor superfamily members 
(Claudio et al., 2002; Shinkura et al., 1999; Willmann et al., 2014), Epstein-Barr virus 
infection (Eliopoulos et al., 2003) and malignancy (Cormier et al., 2013; Ranuncolo et 
al., 2012; Vallabhapurapu et al., 2015; Wharry et al., 2009).  
NcNF-kB signaling is a complex pathway with slower activation kinetics 
compared with classical NF-kB. It is initiated by the stabilization of NF-kB-Inducing 
Kinase (NIK), which is K48-polyubiqutinated by cIAP1 and 2 and constitutively 
degraded by the proteasome (Sun, 2017). Upon TNFRSF trimerization by its ligand, 
differential TNF Receptor Associated Factor (TRAF) recruitment shifts cIAP1/2-
mediated K48 polyubiquitination from NIK to TRAF3, thereby alleviating the continuous 
K48 polyubiquitination-mediated degradation of NIK. NIK accumulates and coordinates 
a protein complex including Inhibitor of NF-kB Kinase alpha (IKKα), and the Rel 
homology domain family members RelB and p100, the latter two of which form a 
heterodimer that is basally sequestered in the cytoplasm. Accumulating NIK 
phosphorylates IKKα, which in turn phosphorylates p100, creating a phosphodegron that 
leads to partial degradation by the proteasome to form p52.  The newly formed RelB/p52 
heterodimer then translocates to the nucleus where it mediates transcriptional control of 
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numerous genes involved in lymphoid development (Sun, 2017), mitochondrial 
biogenesis in skeletal muscle and osteoclasts (Bakkar et al., 2012; Zeng et al., 2015), and, 
in cancer cells, synergizes with ERK to suppress proapoptotic genes Bim and BMF 
(Vallabhapurapu et al., 2015). This complex signaling pathway is illustrated 
schematically in Figure 1.3. 
Like 4-1BB, ncNF-kB signaling is also essential for T cell immunity. Memory T 
cells require ncNF-kB signaling to survive both in mice (Li et al., 2016; Rowe et al., 
2013) and in humans; the latter requirement was revealed by a deficiency of long-lived 
memory T cells in two patients with biallelic loss-of-function mutations in NIK 
(Willmann et al., 2014). Similarly, mice deficient in NIK form few persistent memory T 
cells when challenged with acute LCMV infection (Rowe et al., 2013). This loss was 
found to be cell-intrinsic as T cell-specific NIK KO mice have substantially fewer 
circulating memory T cells than WT controls (Li et al., 2016). 
Based upon the importance of ncNF-kB signaling to T cell memory formation and 
the report of activation of this pathway by endogenous 4-1BB in murine T cells, we 
evaluated the activation and role of this pathway in human CAR T cells.  We show that 
ncNF-kB signaling plays an essential role in supporting BBz CAR T cell survival. In 
addition to providing greater insight into the costimulatory mechanisms of the CD28 and 
4-1BB domains in CARs, the increased understanding of the role of this pathway in 
human T cells offers opportunities to manipulate it more broadly in T cell-based 
immunotherapies that rely upon T cell survival to mediate clinical benefit. 
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RESULTS 
4-1BB costimulation enhances ex vivo CAR T cell expansion relative to CD28 
costimulation and is associated with improved T cell survival 
To study the ex vivo expansion of T cells following stimulation by CD19-specific 
CARs bearing different costimulatory domains, we employed the approach of repeated in 
vitro stimulation (Drent et al., 2019; Feucht et al., 2019; Milone et al., 2009; Zhao et al., 
2015). We added irradiated Nalm6 leukemic cells bearing the CD19 target antigen to 
mCherry-expressing 28z or BBz CAR T cell cultures (Figure 2.1A) at 7-day intervals as 
shown in a representative growth curve in Figure 2.1B. Similar to prior studies 
comparing CD28 and 4-1BB (CD137) costimulated CARs, T cells bearing a 4-1BB 
costimulated CAR (BBz CAR T cells) accumulated over 14 days to yield approximately 
1-log more T cells than CD28-costimulated CAR T cells (28z CAR T cells) (Figure 
2.1C). This increased expansion is associated with improved viability, which we 
observed by a 14% (+/- 3.2%) absolute reduction in T cells that acquired 7AAD 
fluorescence and lost mCherry expression on Day 14 for BBz CAR T cells relative to 28z 
CAR T cells (Figure 2.1D). To determine if there was also a difference in relative 
proliferation, we measured expression of proliferating cell nuclear antigen (PCNA) by 
immunoblot (Figure 2.1E) and found no significant difference in PCNA expression 
between 28z and BBz CAR T cells at day 0, 7 or 14 following CAR restimulation 
(Figure 2.1F). 
 
32 
 
To identify signaling pathways that drive enhanced BBz CAR T cell survival, we 
employed a bead-based artificial antigen presenting cell (APC) approach for activating 
CD19-specific CAR T cells. We used magnetic microbeads coated with anti-CD19 
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Figure 2.1: Irradiated target cell-mediated 4-1BB-costimulated CAR activation 
drives greater ex vivo T cell expansion and survival than CD28-costimulated 
CAR activation. (A) Representative flow plot of anti-CD19 28z and BBz CAR 
expression. (B) Representative ex vivo expansion of CAR T cells stimulated by 
irradiated Nalm6 target cells at indicated time points (2:1 T cell to target cell ratio). 
(C) Quantification of T cell expansion after 14 days of ex vivo culture represented in 
A. (D) Quantification of cell death by % 7AAD+ mCherry- of all events collected on 
day 14 of ex vivo culture represented in A. (E) Representative immunoblot of 
proliferating cell nuclear antigen (PCNA) at 0, 7, and 14 days of ex vivo culture with 
Nalm6 target cells. (F) Immunoblot analysis of PCNA expression on day 14 of ex 
vivo culture with Nalm6 target cells. B, C, E n=3 donors from 2 independent 
experiments, paired student’s t test. 
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idiotype antibodies to crosslink the anti-CD19 CAR. This approach avoids the 
introduction of target cell proteins and RNA that confound analyses of signaling and does 
not add additional signals to the CAR T cells through other costimulatory interactions 
such as integrin and CD28 activation (Li et al., 2013). Furthermore, such beads have been 
used by our group and others to study CAR signaling and its impact on T cell expansion, 
metabolism and differentiation (Kawalekar et al., 2016; Ramello et al., 2019; Salter et al., 
2018). Similar to the studies using activation by Nalm6 leukemic cells, BBz CAR T cells 
activated by aAPCs also expand about a log more than 28z CAR T cells (Figures 2.2A-
C). These expansions were less than those achieved with the irradiated target cells, likely 
due to a loss of additional costimulatory signals provided by those cells. Even so, we 
observed a 8.9% (+/- 3.1%) absolute reduction in 7AAD+, mCherry- cells on Day 14 of 
BBz CAR T cells relative to 28z CAR T cells (Figure 2.2D) and did not detect a 
significant difference in PCNA expression (Figure 2.2E). From these data, we conclude 
that our bead-based expansion system achieves similar outcomes as the irradiated cell 
system. 
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CAR intracellular domains activate overlapping, but kinetically and quantitatively 
distinct signaling pathways upon antigen stimulation 
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Figure 2.2: Antigen-coated bead ex vivo expansion system recapitulates relative 
expansion, survival, and proliferative differences between 4-1BB- and CD28-
costimulated CAR T cells. (A) Representative flow plot of anti-CD19 28z and BBz 
CAR expression. (B) Representative ex vivo expansion of CAR T cells stimulated by 
anti-CD19 idiotype-coated target beads (1:3 T cell to bead ratio) added at day 0 (green 
arrow) and removed at day 14 of culture (black arrow). (C) Quantification of T cell 
expansion after 14 days of ex vivo culture represented in B. (D) Quantification of cell 
death by % 7AAD+ mCherry- of all events collected on day 14 of ex vivo culture 
represented in B. C, D n=3 donors from 3 independent experiments, paired student’s t 
test. (E) Quantification of western blot analysis of proliferating cell nuclear antigen 
(PCNA) at the beginning of, 7, and 14 days of ex vivo culture with target beads (n=3 
donors from 3 independent experiments, paired student’s t test). 
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Both proximal and distal signaling pathways activated by the endogenous TCR 
and costimulatory molecules have been reported to influence the proliferation and 
survival of T cells following CAR activation (D'Souza et al., 2008; Liu et al., 2016; 
Salojin et al., 1999). To determine the kinetics of BBz CAR signaling in our bead-based 
system, we assessed p65, and ERK1/2 phosphorylation in BBz CAR T cells at the 
indicated intervals over 48 hours (Figure 2.3A). We observed an initial change from 
baseline in both pathways within 30 minutes of BBz CAR activation, with ERK1/2 
phosphorylation having the largest increase from baseline (Figures 2.3B-D). ERK1/2 
phosphorylation did not change further until 12-24 hours following CAR activation, 
likely reflecting the activity of CAR-activation induced cytokine production and 
signaling (Figure 2.3C-D).  
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To validate that our bead-based activation system drives similar relative kinetics 
in these T cell signaling pathways as has recently been reported (Salter et al., 2018), we 
compared Zap-70, p65, and ERK1/2 phosphorylation in T cells expressing an anti-CD19 
CAR containing no signaling domains (Dz), the CD3 zeta chain alone (z), also known as 
a first-generation CAR, or one of two second-generation combinations, 28z, or BBz 
(Figures 2.4 and 2.5). Similar to recent work by Salter et al., 28z CAR mediated Zap70 
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Figure 2.3: Anti-CD19 BBz CAR activation induces T cell signaling. (A) 
Representative immunoblot of p65 and ERK1/2 phosphorylation at the indicated time 
points after stimulator bead addition to BBz CAR T cells. (B) Quantification of p65 
phosphorylation represented by the immunoblot in A. (C) Quantification of ERK1 
phosphorylation represented by the immunoblot in A. (D) Quantification of ERK2 
phosphorylation represented by the immunoblot in A. A-D n=3 independent 
experiments with 3 donors. 
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phosphorylation was 4.5-fold higher than that mediated by BBz CAR 12 hours after bead 
addition and 3.7-fold higher than that mediated by z CAR 30 minutes after bead addition 
(Figure 2.5B). p65 phosphorylation at Serine 536, a measure of canonical NF-kB 
signaling, increased across all signaling CARs after bead addition, with a trend toward 
increased p65 phosphorylation early after activation of the 28z CAR and a small, but 
significant increase of 1.34-fold in the BBz CAR relative to that in the 28z CAR at 12 hrs 
(Figure 2.5C). Also like the recent work by Salter et al., ERK1 and 2 phosphorylation 
both increased with activation of all signaling CARs over time (Figures 2.5D-E) with 
ERK2 phosphorylation increased 2.2- and 1.9-fold by 28z and BBz CAR activation, 
respectively, relative to that by z-only CAR activation at 30 minutes (Figure 2.5E). We 
conclude from these data that the bead-based APC system activates anti-CD19 CARs 
leading to CAR signaling in a similar manner to that reported in the literature (Kawalekar 
et al., 2016; Salter et al., 2018), providing a robust system for evaluating signaling 
downstream of our CD19-specific CARs. 
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red, BBz CAR in blue. 
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4-1BB, but not CD28, co-stimulation potentiates CAR-mediated non-canonical NF-kB 
signaling 
We hypothesized that the 4-1BB intracellular domain incorporated into a CAR 
specifically promotes CAR T cell survival and persistence through activation of ncNF-kB 
signaling. In order to interrogate this pathway and establish optimal time points for 
comparison across CAR constructs, we first determined the kinetics of activation 
following engagement of the BBz CAR (Figure 2.6A). Expression of the initiator kinase 
for this pathway, NIK, increased significantly following BBz CAR activation with a peak 
of 8.7-fold over baseline also at 12 hours after CAR activation. (Figure 2.6B). We 
measured downstream ncNF-kB signaling using the commonly reported metrics of p100 
processing: p100 phosphorylation (Figure 2.6C) and p52/p100 ratio (Figure 2.6D) 
(Remouchamps and Dejardin, 2015). p100 phosphorylation increased significantly 
following bead addition, peaking at 6.1-fold over baseline at 12 hours (Figure 2.6C). 
Similarly, the p52/p100 ratio increased significantly over the first twelve hours following 
BBz CAR activation, with a peak of 1.87 fold over baseline at 12 hours (Figure 2.6D). 
Figure 2.5 (Previous Page): Anti-CD19 idiotype target beads activate T cell 
signaling in anti-CD19 CAR-expressing T cells. (A) Representative western blot of 
Zap-70, p65, and ERK1/2 phosphorylation prior to, 30 minutes, and 12 hours after 
bead addition to T cells (5:1 bead-to-T cell ratio) expressing anti-CD19 CARs with no 
signaling domain (Dz), the CD3z chain intracellular domain only (z), CD28 and CD3z 
chain intracellular domains (28z), or 4-1BB and CD3z chain intracellular domains 
(BBz). Quantification of western blot analysis of Zap-70 (B), p65 (C), ERK1 (D), and 
ERK2 (E) phosphorylation shown in A (green=z, red=28z, and blue=BBz; 
quantifications of band fluorescence normalized to loading control, p-values reported 
from two-way ANOVA with Tukey’s multiple comparisons test from 3 donors from 3 
independent experiments. 
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NcNF-kB signaling culminates in nuclear translocation of RelB and p52. Therefore, we 
also measured RelB and p52 nuclear translocation in isolated nuclear fractions, as 
confirmed by loss of vinculin (Figure 2.7), at similar time points following BBz CAR 
activation using the same initial setup as our assessment of NIK and p100 signal 
transduction. Cytoplasmic RelB increased and stayed above baseline after 8 hours of 
bead stimulation (Figure 2.7), reflecting previously described increases in expression 
following canonical NF-kB signaling (Sanchez-Paulete et al., 2016). Critically, both 
RelB and p52 nuclear localization were detectable prior to and increased after BBz CAR 
activation (Figure 2.7) indicating tonic signaling and further antigen-mediated activation 
of the ncNF-kB pathway. Consistent with the delayed kinetics of this pathway relative to 
that of the canonical NF-kB pathway (McPherson et al., 2012), we observed peak ncNF-
kB signaling 12 hours after anti-CD19 BBz CAR activation. 
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Figure 2.6: 4-1BB-costimulated anti-CD19 CAR activation induces non-canonical 
NF-kB signaling. (A) Representative immunoblots of NIK stabilization and p100 
processing at the indicated times before and after target bead addition to anti-CD19 
BBz CAR T cells.  (B) Quantitative analysis of immunoblot represented in A of NIK 
stabilization (p=0.011). Quantitative analyses of immunoblots represented in A of 
p100 phosphorylation (C, p=0.0397), and p100 processing to p52 (D, p52/p100 ratio, 
p=0.0244). All p-values generated from 2 independent experiments using CAR T cells 
derived from 3 healthy donors by one-way ANOVA from 0.5 to 12-hour time points 
of Log2 (Fold Change relative to signal prior to bead addition). 
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To test the hypothesis that ncNF-kB signaling is uniquely activated by 4-1BB co-
stimulated CARs, we compared ncNF-kB signaling by anti-CD19 targeted Dz, z, 28z, or 
BBz CARs prior to activation, at 30 minutes, and at 12 hours after bead addition (Figure 
2.8A). NIK stabilization trended higher following BBz CAR activation relative to the 
other CARs (Figure 2.8B), but this trend was not statistically significant. p100 
phosphorylation was 3.2-fold higher 12 hours after bead addition to BBz CAR T cells 
relative to 28z CAR T cells (Figure 2.8C). We observed a similar trend in p100 
phosphorylation comparing the BBz and z-only CARs. The p52/p100 ratio was increased 
in BBz CAR T cells relative to 28z CAR T cells across all time points including prior to 
activation (range 1.8- to 2.4- fold higher), whereas no difference in the p52/p100 ratio 
was observed between the 28z and z-only CARs (Figure 2.8D). The downstream basal 
Time
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Cytoplasmic Nuclear
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p52
TBP
Vinculin
Figure 2.7: 4-1BB-costimulated anti-CD19 CAR activation RelB/p52 nuclear 
translocation. Representative immunoblot of cytoplasmic and nuclear fractions prior 
to and at the indicated times after target bead addition to anti-CD19 BBz CAR T cells. 
Vinculin used as marker of cytoplasmic fraction and Tata-binding protein (TBP) used 
as nuclear loading control (representative of 2 separate experiments using CAR T cells 
generated from 2 healthy donors). 
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ncNF-kB signaling in BBz CAR T cells relative to 28z CAR T cells was also reflected in 
increased baseline RelB nuclear occupancy (Figure 2.9A), which was 1.3-fold higher in 
BBz CAR T cells relative to 28z CAR T cells (Figure 2.9B). RelB nuclear translocation 
increased further 12 hours after CAR activation and was 5.4-fold higher in BBz CAR T 
cells relative to 28z CAR T cells (Figure 2.9B). Though we observed increased p52 
nuclear occupancy in BBz CAR T cells across all time points relative to z or 28z (Figure 
2.9A), this increase reached statistical significance for BBz vs. 28z only at the 30 minute 
time point and for BBz vs z only at the 12 hour time point (Figure 2.9C). 
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Figure 2.8: Anti-CD19 4-1BB, but not CD28, CAR costimulation drives basal and 
enhances CAR activation-induced non-canonical NF-kB signaling. (A) 
Representative immunoblots of NIK stabilization and p100 processing at the indicated 
times before and after target bead addition to T cells (5:1 bead-to-T cell ratio) 
expressing anti-CD19 CARs with no signaling domain (Dz), the CD3z chain 
intracellular domain only (z - green), CD28 and CD3z chain intracellular domains 
(28z - red), or 4-1BB and CD3z chain intracellular domains (BBz - blue). (B) 
Quantitative analysis of immunoblot represented in A of NIK stabilization. 
Quantitative analyses of immunoblot represented in A of p100 phosphorylation (C), 
and p100 processing to p52 (D). (n=3 donors in 3 independent experiments for all 
Log2(Fold Change relative to non-signaling group) quantifications of band 
fluorescence normalized to loading control, p-values reported from two-way ANOVA 
with Tukey’s multiple comparisons test). 
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To confirm the unique association between the BBz CAR and ncNF-kB signaling 
in a CAR with an alternative scFv and antigen specificity, we compared the p52/p100 
ratio in SS1-28z or SS1-BBz CARs targeting mesothelin (Figures 2.10A-B) prior to 
activation, at 30 minutes, and at 12 hours after mesothelin-coated bead addition (Figure 
Figure 2.9: Anti-CD19 4-1BB, but not CD28, CAR costimulation drives basal and 
enhances CAR activation-induced RelB/p52 nuclear translocation. (A) 
Representative immunoblot of RelB, p52, and TBP in nuclear fractions prior to and at 
the indicated times after target bead addition to anti-CD19 CAR T cells as in A. 
Quantitative analyses of immunoblots represented in A of nuclear RelB (B), and 
nuclear p52 (C). (n=3 donors in 3 independent experiments for all Log2(Fold Change 
relative to non-signaling group) quantifications of band fluorescence normalized to 
loading control, p-values reported from two-way ANOVA with Tukey’s multiple 
comparisons test). 
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2.10C). Similar to CD19-specific BBz CAR, we observed a higher p52/p100 ratio in the 
SS1-BBz CAR compared to SS1-28z CAR in two separate donors prior to activation 
(Figures 2.10C-D). Unlike the CD19 CAR, the p52/p100 ratio decreases following 
mesothelin-coated bead addition in the SS1-BBz CAR T cells, but it remains higher than 
the SS1-28z CAR T cells under the same conditions.  
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In aggregate, these data demonstrate that the BBz signaling domain within the 
CAR basally activates the ncNF-kB pathway. Although the degree of antigen-induced 
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Figure 2.10: Anti-mesothelin BBz CAR also drives non-canonical NF-kB 
signaling. (A) Modular representations of the anti-mesothelin CARs used. (B) 28z 
(red) and BBz (blue) CAR expression of live cells from two donors by flow 
cytometry. (C) p100 processing to p52 prior to, and following mesothelin-coated bead 
addition to CAR T cells from two donors at times indicated. (D) p100 processing to 
p52 prior to, and following mesothelin-coated bead addition to CAR T cells from two 
donors 2 at times indicated. 
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enhancement of ncNF-kB signaling by BBz CARs differs between the scFv and/or nature 
of the ligand, BBz CARs exhibit greater ncNF-kB signaling compared to 28z CARs. 
Expression of a dominant-negative NF-kB-inducing-kinase mutant reduces BBz-
mediated non-canonical NF-kB signaling, ex vivo BBz CAR T cell expansion, and 
survival 
Targeting NIK has been a widely used strategy to block non-canonical NF-kB 
signaling (Sun, 2012). Therefore, we employed this approach to interrupt ncNF-kB 
signaling downstream of BBz CAR activation by overexpressing the c-terminus of NIK 
(dnNIK) in CAR T cells. DnNIK acts as a dominant-negative mutant by binding p100 
and thereby preventing downstream ncNF-kB signaling (Xiao et al., 2001). We 
transduced BBz CAR T cells 24 hours after initially transducing the primary human T 
cells with the BBz CAR with either a control vector expressing only mCherry, or a 
bicistronic vector expressing dnNIK and mCherry (Figure 2.11). This strategy allowed us 
to compare ncNF-kB signaling in each group by immunoblotting while maintaining equal 
CAR expression across groups (Figure 2.12). We observed a 1.5-fold decrease in 
p52/p100 ratio 12 hours after CAR activation in dnNIK expressing T cells relative to 
control (Figures 2.13A-B). Similarly, we observed 1.4- and 1.9-fold decreases in RelB 
nuclear occupancy 30 minutes and 12 hours, respectively, after BBz CAR activation in 
dnNIK expressing T cells relative to control (Figures 2.13C-D). We observed a similar 
trend in p52 nuclear occupancy, with significant decreases of 1.9- and 2-fold at baseline 
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and 12 hours post CAR activation, respectively, in dnNIK expressing T cells relative to 
control (Figures 2.13C, E). 
Having observed a reduction in non-canonical NF-kB signaling by dnNIK 
expression, we used this approach in the bead-based CAR T cell expansion model to test 
the hypothesis that ncNF-kB signaling is a mediator of anti-CD19 4-1BB co-stimulated 
CAR T cell survival.  
We observed that dnNIK-expressing BBz CAR T cells expanded 3.1-fold less 
than control BBz CAR T cells 14 days after anti-CD19 idiotype bead addition (Figures 
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Figure 2.11: Dual transduced T cell production scheme. Dual transduction 
schematic for dominant-negative NIK (dnNIK) CAR T cells. 
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2.14A-B). This reduction in expansion was associated with a 6.2% absolute increase in 
cell death assessed by 7AAD uptake by flow on day 14 (Figure 2.14C). We did not detect 
a significant difference in PCNA expression between control and dnNIK-expressing BBz 
CAR T cells prior to or 14 days after CAR T cell activation (Figure 2.14D). To exclude 
that dnNIK expression was non-specifically causing CAR T cell death following CAR 
activation, we conducted these studies in anti-CD19 28z CAR T cells in parallel (Figure 
2.15). We observed no significant differences in expansion (Figures 2.15A-B), 7AAD 
uptake (Figure 2.15C), or PCNA expression (Figure 2.15D) between control and dnNIK-
expressing 28z CAR T cells on day 14 of culture. These data demonstrate that 4-1BB-
costimulated anti-CD19 CAR T cells specifically require ncNF-kB signaling to promote 
cell survival. 
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CD19 BBz CAR expression immediately prior to activation with anti-CD19 idiotype 
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Figure 2.13 (Previous Page): Dominant-negative NIK expression reduces non-
canonical NF-kB signaling. (A) Representative immunoblot of p100 processing to 
p52 at indicated times after target bead addition to anti-CD19 BBz CAR T cells 
expressing either mCherry (control) or dnNIK. (B) Quantitative analysis of p52/p100 
ratio from immunoblots represented in A. (Quantification in A performed on p52/p100 
ratio. Analysis in B performed on Log2 of fluorescence of p52/p100 ratio of 3 
independent experiments of CAR T cells generated from 3 donors. P-values reported 
from 2-way ANOVA with Holm-Sidak’s multiple comparisons test.) (C) 
Representative immunoblot of RelB, p52, and TBP in nuclear fractions of anti-CD19 
BBz CAR T cells as in A. Quantitative analyses of nuclear localization of RelB (D) 
and p52 (E) from immunoblots represented in C. (Quantification in C performed on 
RelB or p52 normalized to TBP loading control. Analysis in D and E performed on 
Log2 of fluorescence of protein of interest normalized to the fluorescence of TBP from 
2 independent experiments of CAR T cells generated from 3 donors. P-values reported 
from 2-way ANOVA with Holm-Sidak’s multiple comparisons test.) 
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Figure 2.14: Dominant-negative NIK-mediated non-canonical NF-kB suppression 
diminishes BBz CAR T cell ex vivo expansion and survival. (A) Representative ex 
vivo expansion of control or dnNIK BBz CAR T cells stimulated by anti-CD19 
idiotype-coated target beads (1:3 T cell to bead ratio) added at day 0 (green arrow) and 
removed at day 14 of culture (black arrow). (B) Quantification of T cell expansion 
after 14 days of ex vivo culture represented in A. Quantification of cell death by % 
7AAD+ mCherry- of all events collected (C) and PCNA expression (D) on day 14 of 
ex vivo culture represented in A. All p-values derived from paired student’s t-tests 
from 4 donors in 4 independent experiments. 
55 
 
Oxidative metabolism is unaffected by non-canonical NF-kB blockade 
Cell-intrinsic and TNFRSF-mediated ncNF-kB signaling in skeletal muscle fibers 
and osteoclasts, respectively, drives oxidative metabolism (Bakkar et al., 2012; Zeng et 
al., 2015). Oxidative metabolism supports memory T cell survival (van der Windt et al., 
2012), and central memory T cells are enriched by anti-CD19 BBz CAR activation 
(Kawalekar et al., 2016). We determined that BBz CARs activate ncNF-kB signaling, 
which supports anti-CD19 BBz CAR T cell survival. From these observations, we 
hypothesized that the reduced survival of dnNIK-expressing BBz CAR T cells is due at 
least in part to a loss in oxidative metabolism. To test this hypothesis, we measured the 
oxygen consumption and extracellular acidification rates of control or dnNIK-expressing 
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Figure 2.15: Dominant-negative NIK-mediated non-canonical NF-kB suppression 
has no effect on 28z CAR T cell ex vivo expansion and survival. (A) 
Representative ex vivo expansion of control or dnNIK 28z CAR T cells stimulated by 
anti-CD19 idiotype-coated target beads (1:3 T cell to bead ratio) added at day 0 (green 
arrow) and removed at day 14 of culture (black arrow). (B) Quantification of T cell 
expansion after 14 days of ex vivo culture represented in A. Quantification of cell 
death by % 7AAD+ mCherry- of all events collected (C) and PCNA expression (D) 
on day 14 of ex vivo culture represented in A. All p-values derived from paired 
student’s t-tests from 4 donors in 4 independent experiments. 
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anti-CD19 BBz CAR T cells before and 14 days after anti-CD19 idiotype bead-based 
bead activation (Figure 2.16). We observed no differences in basal or maximal oxygen 
consumption rate (Figure 2.16A) or extracellular acidification rate (Figure 2.16B) 
between control and dnNIK-expressing cells at either time point. We did observe that day 
14 cells have a higher basal and maximal ECAR than their unstimulated counterparts 
(Figure 2.16B). This increased ECAR reflects that the T cells have been activated, as is 
consistent with previous reports (MacIver et al., 2013). From these data, we conclude that 
ncNF-kB signaling is not responsible for supporting oxidative metabolism in anti-CD19 
BBz CAR T cells. 
 
57 
 
4-1BB costimulation-mediated non-canonical NF-kB signaling represses pro-apoptotic 
protein, Bim 
NcNF-kB signaling in multiple myeloma cell lines and 4-1BB costimulation in T 
cells have both been shown to enhance cell survival by suppressing expression of the pro-
apoptotic protein Bim (Sabbagh et al., 2008; Vallabhapurapu et al., 2015; Wang et al., 
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Figure 2.16: Dominant-negative NIK expression does not impact BBz CAR T cell 
oxygen consumption or glycolysis. (A) Control (blue) and dnNIK (red) anti-CD19 
BBz CAR T cell oxygen consumption rate prior to and 14 days after bead expansion. 
First three data points represent basal oxygen consumption and third set of data points 
represent maximal oxygen consumption induced by FCCP. (B) Extracellular 
acidification rate of these cells on days indicated. First three data points represent 
basal glycolytic rate. Second set of three represent maximal glycolytic rate induced by 
oligomycin. 
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2008). From our observation that ncNF-kB signaling supported BBz CAR T cell 
survival, we hypothesized that the increased cell death observed with reduced ncNF-kB 
signaling in BBz CAR T cells is due at least in part to increased Bim expression. To 
evaluate this, we assessed Bim expression by immunoblot at baseline and 14 days after 
anti-CD19 idiotype bead addition in CD19-specific BBz (Figure 2.17) and 28z (Figure 
2.18) CAR T cells transduced with a dnNIK or a control vector. No significant difference 
was detected in any of the Bim isoforms at baseline between dnNIK or control transduced 
BBz (Figure 2.17B-D) or 28z (Figure 2.18B-D) CAR T cells. BimL expression was 
significantly higher in BBz cells transduced with the dnNIK vector when compared to the 
control vector at day 14 (Figure 2.17F) with a similar trend observed for BimS (Figure 
2.17G). No difference in any of the isoforms of Bim was apparent in 28z CAR T cells at 
day 14 (Figure 2.18E-G). 
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Figure 2.17: 4-1BB-costimulation-mediated non-canonical NF-kB signaling 
opposes expression of pro-apoptotic protein, Bim. (A) Representative western blot 
of Bim isoform expression prior to and 14 days after ex vivo bead expansion in control 
or dnNIK BBz CAR T cells. Quantitation of western blot of baseline BimEL (B), BimL 
(C), and BimS (D) expression, and expression of BimEL (E), BimL (F), and BimS (G) 
14 days after bead addition as represented in A. B-G All p-values derived from paired 
student’s t-tests from 4 donors in 4 independent experiments. 
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Figure 2.18: DnNIK expression does not influence 28z CAR T cell Bim 
expression. (A) Representative western blot of Bim isoform expression prior to and 
14 days after ex vivo bead expansion in control or dnNIK 28z CAR T cells. 
Quantitation of western blot of baseline BimEL (B), BimL (C), and BimS (D) 
expression (n=3 independent experiments with 3 donors; p-values derived from paired 
student’s t-tests. No pre-bead sample was taken for 4th donor shown in E-G). and 
expression of BimEL (E), BimL (F), and BimS (G) 14 days after bead addition as 
represented in A. E-G All p-values derived from paired student’s t-tests from 4 donors 
in 4 independent experiments. 
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Comparing Bim isoform expression between 28z and BBz CAR T cells at baseline 
(Figure 2.19) demonstrated a significant decrease in BimS in BBz cells (Figure 2.19C) 
with a similar trend in BimL (Figure 2.19B). Together, the differential Bim isoform 
expression observed prior to CAR activation between 28z and BBz CAR T cells with 
especially low levels of BimS expression in BBz cells and the increase in Bim isoform 
expression in the context of dnNIK following CAR activation are consistent with Bim as 
a target of ncNF-kB signaling in BBz CAR T cells. The failure to detect a difference in 
Bim isoform expression when ncNF-kB signaling is disrupted by dnNIK prior to CAR 
activation may be a result of the low overall expression of the BimS and BimL. 
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Though previous work in multiple myeloma cell lines has demonstrated 
cooperative suppression of Bim by ERK and non-canonical NF-kB signaling 
(Vallabhapurapu et al., 2015), prior studies in T cells have only addressed ERK-mediated 
Bim suppression (Luciano et al., 2003; O'Reilly et al., 2009; Sabbagh et al., 2008). 
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Figure 2.19: In the absence of antigen, anti-CD19 BBz CAR T cells express less of 
the two most potent isoforms of Bim than 28z CAR T cells. Quantitation of western 
blots of baseline  BBz and 28z CAR T cell BimEL (A), BimL (B), and BimS (C) 
expression and expression of BimEL (D), BimL (E), and BimS (F) 14 days after 
BBz and 28z CAR T cells were activated by anti-CD19 idiotype beads. All p-values 
derived from paired student’s t-tests from 3 donors in 3 independent experiments. 
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Therefore, we assessed ERK phosphorylation in the dnNIK-expressing BBz CAR T cells 
to determine if dnNIK expression impacted BBz CAR-mediated ERK activation (Figure 
2.20A). Thirty minutes after bead addition, we observed a 1.2-fold reduction in ERK1 
phosphorylation in dnNIK-expressing CAR T cells relative to controls, but no significant 
difference in ERK1 phosphorylation prior to or 12 hours after bead addition (Figure 
2.20B). We also observed no significant difference in ERK2 phosphorylation at any time 
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Figure 2.20: Control vs. dnNIK BBζ CAR T cell ERK1/2 Phosphorylation. (A) 
Representative immunoblot of ERK1/2 phosphorylation at the indicated time points 
after stimulator bead addition to BBz CAR T cells expressing mCherry (control) or 
dominant-negative NIK (dnNIK). (B) Quantification of ERK1 phosphorylation 
represented by the immunoblot in A. (C) Quantification of ERK2 phosphorylation 
represented by the immunoblot in A. P-value from 2-way ANOVA with Holm-Sidak’s 
multiple comparisons test of 3 independent experiments from 3 donors. 
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point (Figure 2.20C). Thus, although the reduction in ERK1 phosphorylation upon 
activation in dnNIK-expressing CAR T cells is small and transient, we cannot completely 
rule out that the observed reductions in Bim expression are not in part due to small 
reductions in ERK signaling. 
Another transcription factor known to drive Bim expression in T cells is FOXO3a 
(Riou et al., 2007). FOXO3a is regulated by numerous signaling pathways, including by 
g-chain cytokines through phosphorylation of threonine 32 and subsequent proteosomal 
degradation (Riou et al., 2007; Sunters et al., 2003). To determine if g-chain cytokine 
signaling is affected by dnNIK expression  and impacts Bim expression through FOXO3a 
regulation, we assessed FOXO3a phosphorylation at threonine 32 and total FOXO3a 
expression in the control and dnNIK-expressing BBz CAR T cells at Day 0 and Day 14 
of expansion (Figure 2.21). We observed no significant differences in FOXO3a 
expression between the control and dnNIK-expressing groups at either timepoint (Figure 
2.21B), instead observing a loss of FOXO3a expression from D0 to D14. We were also 
unable to detect any phosphorylation of FOXO3a at threonine 32 in any of the samples 
(Figure 2.21A). Instead, we detected phosphorylation of FOXO1 at threonine 34, which 
can be distinguished by its smaller size relative to FOXO3a (Figure 2.21A). From these 
data, we conclude that FOXO3a is not being modulated by dnNIK expression and is 
unlikely to contribute to changes in Bim expression. 
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DISCUSSION 
We have shown that the 4-1BB cytoplasmic domain incorporated into a CAR 
potently activates non-canonical NF-kB signaling in human T cells. This activation 
appears constitutive across two 4-1BB-costimulated CARs with independent antigenic 
specificity, and it is also increased in CD19-specific BBz CAR T cells upon CAR 
engagement with ligand when compared with a 1st generation CAR or a CD28-
costimulated CAR. Moreover, disruption of this pathway significantly impairs anti-CD19 
CAR T cell survival following BBz CAR-mediated activation leading to reduced T cell 
expansion ex vivo.  The latter is associated with increased expression of the pro-apoptotic 
protein, Bim, shown to mediate the pro-survival effects of ncNF-kB signaling in other 
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Figure 2.21: Control vs. dnNIK BBζ CAR T cell FOXO3a Phosphorylation and 
Expression. (A) Representative immunoblot of FOXO3a/FOXO1 phosphorylation 
and FOXO3a expression at the indicated time points after stimulator bead addition to 
anti-CD19 BBz CAR T cells expressing mCherry (control) or dominant-negative NIK 
(dnNIK). (B) Quantification of FOXO3a expression represented by the immunoblot in 
A. P-values calculated using 2-way ANOVA with Tukey’s multiple comparisons test 
of 3 independent experiments from 3 donors. 
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systems (Vallabhapurapu et al., 2015; Wang et al., 2008). Our study is the first to our 
knowledge to demonstrate that the 4-1BB costimulatory domain within a CAR directly 
promotes T cell survival via the non-canonical NF-kB pathway, consistent with previous 
reports demonstrating that murine endogenous 4-1BB costimulation activates the ncNF-
kB signaling (McPherson et al., 2012), whereas endogenous CD28 costimulation does 
not (Li et al., 2005; Marinari et al., 2004).  It also adds to our understanding of CAR 
costimulation as prior published reports have implicated faster and more potent proximal 
signaling by CD28-costimulated CARs to explain the differences between 4-1BB and 
CD28 costimulated CAR T cell survival (Salter et al., 2018) whereas our results provide 
an additional mechanism directed by the 4-1BB domain itself.   
A frequently observed feature of 4-1BB co-stimulated CARs is basal signaling in 
the absence of antigen, so called “tonic” signaling (Ajina and Maher, 2018; Frigault et al., 
2015; Milone et al., 2009). Our data is consistent with these previous reports, and we also 
observe CD28-costimulated CAR basal signaling through the Zap70 pathway (Figures 
2.5A-B, (Salter et al., 2018)). 4-1BB-costimulated CAR basal signaling appears to occur 
through both the canonical (Figure 2.5A, C, (Li et al., 2018)) and non-canonical (Figures 
2.6-10) NF-kB pathways, with the latter detectable by increased baseline p100 processing 
(Figure 2.8D and 2.10D) and RelB nuclear localization (Figure 2.9B). This basal ncNF-
kB signaling is consistent across anti-CD19 and anti-mesothelin CARs. Intriguingly, not 
all pathways downstream of CAR activation are basally active. ERK phosphorylation is 
undetectable prior to CAR activation (Figures 2.5A, D-E), and ERK2 phosphorylation, 
specifically at 30 minutes post CAR activation, was a statistically significant marker of 
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costimulation (Figure 2.5E). These distinct signaling modalities of CARs may arise from 
the constitutive dimerization of the CAR caused by disulfide bridges between the CD8 
hinge domains or associations between neighboring scFv’s (Harris and Kranz, 2015; 
Snow and Terhorst, 1983). Though the native 4-1BB can form dimers linked by disulfide 
bonds (Bitra et al., 2018), trimerization by its ligand, 4-1BBL, initiates downstream 
signaling (Bitra et al., 2018; Gilbreth et al., 2018b; Won et al., 2010; Zapata et al., 2018; 
Zheng et al., 2010). Whereas CD28-costimulated CAR basal signaling has been 
consistently shown to be detrimental to CAR T cell function and persistence (Long et al., 
2015; Zheng et al., 2018), basal ncNF-kB signaling enhances cell survival of multiple 
cell types, including T cells (Wang et al., 2008; Wharry et al., 2009). These observations 
are consistent with the BBz CAR-associated enhanced survival of both anti-CD19 
(Milone et al., 2009; Mueller et al., 2018) and anti-mesothelin (Wang et al., 2015) CAR T 
cells. NcNF-kB signaling integrates with ERK and other signaling pathways to achieve 
these effects (House et al., 2018; Li et al., 2015; Liu et al., 2019; Shinzawa et al., 2015; 
Vallabhapurapu et al., 2015), emphasizing the importance of further understanding how 
CARs activate some pathways in the absence of antigen and others only upon 
crosslinking, and how these signals combine to impact T cell function.  
Whereas the basal activation of ncNF-kB signaling was consistent across two 
CARs with different scFv and antigen specificity, the observed difference in ligand-
induced enhancement of the pathway between the CD19-specific and mesothelin-specific 
CAR was unexpected.  We have previously reported on the higher tonic signaling of the 
mesothelin-specific BBz CAR incorporating the SS1 scFv (Frigault et al., 2015). 
68 
 
Although speculative, this increased tonic signaling may lead to higher basal ncNF-kB 
signaling that is closer to the maximal response thereby blunting our ability to see a 
different upon activation. In this case, the small reduction that we observed in the 
p52/p100 ratio following bead activation could be due to increased p100 expression due 
to increased canonical NF-kB signaling (Li et al., 2018; Mukherjee et al., 2017). 
Alternatively, differences in the way that the CAR engages antigen or in the way that the 
antigen is presented for these two scFv-ligand systems might also influence ligand-
dependent activation of the ncNF-kB pathway downstream of a BBz CAR. In particular, 
CARs, like TCR/CD3 complex, internalize following antigen engagement, and the degree 
of internalization has been associated with ligand density as well as receptor affinity, 
which are not controlled in our activation system (Liu et al., 2000; Walker et al., 2017). 
This internalization can negatively impact CAR function (Walker et al., 2017) and could 
lead to diminished ncNF-kB signaling. 
It is likely that the signaling downstream of 4-1BB costimulation that we 
observed will extend to other TNFRSFs that also activate the non-canonical NF-kB 
pathway. Transient expression of OX40L on both activated CD4 and CD8 T cells (Kondo 
et al., 2007; Soroosh et al., 2006) can activate OX40 and downstream ncNF-kB signaling 
(Murray et al., 2011). This OX40-OX40L interaction may explain the small increase in 
ncNF-kB signaling we observed in the z-chain and 28z CARs (Figure 4) as both OX-40 
and OX-40L are inducted upon T cell activation (Soroosh et al., 2006). Other groups 
have incorporated OX40 co-stimulation directly into the CAR, thereby achieving 
enhancements in function and persistence (Hombach and Abken, 2011), likely, at least in 
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part, by activation of ncNF-kB signaling. Similar results may be achieved by using the 
intracellular domains of a number of TNFRSFs that bind TRAF2 and TRAF3 (Sun, 
2017). However, not all TNFRSFs activate non-canonical NF-kB signaling. For example, 
TNFR1 cannot activate ncNF-kB signaling (Festjens et al., 2007; Kim et al., 2011). 
Conversely, BAFFR activates ncNF-kB, but not canonical NF-kB signaling (Stadanlick 
et al., 2008). NcNF-kB signaling in the absence of canonical NF-kB signaling results in 
loss of p100 and attenuation of ncNF-kB signaling (Stadanlick et al., 2008), suggesting 
that domains from TNFRSFs, such as 4-1BB, are most likely to drive CAR T cell 
persistence through a combination of canonical and non-canonical NF-kB signaling. 
 Approaches to pharmacologically activate the ncNF-kB pathway may also have 
utility, especially in T cell-based immunotherapies that do not utilize TNFRSF-based 
costimulation.  One class of molecules, SMAC mimetics, have already been leveraged in 
combination with CAR T cells to enhance target-negative tumor cell killing (Michie et 
al., 2019). SMAC mimetics activate ncNF-kB signaling (Tchoghandjian et al., 2013) and 
enhance T cell expansion and function (Dougan et al., 2010). Based on our observations 
that 4-1BB co-stimulation-mediated ncNF-kB signaling is a driver of anti-CD19 CAR T 
cell survival, it may be possible to use SMAC mimetics to similarly enhance non-
TNFRSF costimulated T cells. This combination may be especially beneficial in 
transgenic T cell receptor directed T cell therapies, which have no synthetic costimulation 
(Krummel et al., 1999). The tumor responses induced by theses therapies correlate with 
persistence (Johnson et al., 2009), which, based on our findings and previous reports of 
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SMAC mimetic effects on T cells (Beug et al., 2017; Dougan et al., 2010), could be 
increased by SMAC mimetic-mediated ncNF-kB signaling. 
Finally, our study has provided some insight into the mechanism by which ncNF-
kB signaling by the 4-1BB domain of the CAR promotes T cell survival. We initially 
hypothesized that ncNF-kB-driven anti-CD19 BBz CAR T cell survival was supported 
by oxidative metabolism. As such, we expected that dnNIK-expressing anti-CD19 BBz 
CAR T cells would have lower maximal oxygen consumption and spare respiratory 
capacity. We were somewhat surprised that we did not detect any differences in either of 
these measurements between control and  dnNIK-expressing anti-CD19 BBz CAR T 
cells both prior to and 14 days after CAR activation (Figure 2.16A). These data suggest 
that BBz CAR-associated oxidative metabolism is driven by other mechanisms. There are 
at least three possible mechanisms that could explain this finding. First, it is still possible 
that NIK stabilization contributes to mitochondrial respiration, but does so by directly 
associating with mitochondria instead of through downstream ncNF-kB signaling (Jung 
et al., 2016). DnNIK only interferes with interactions mediated by the c-terminus of NIK, 
which may not be responsible for its mitochondrial activity. However, BBz CAR-
associated oxidative metabolism was associated with increased expression of TFAM, a 
regulator of mitochondrial biogenesis. Therefore, we believe it is more likely that other 
pathways may be responsible BBz CAR-associated oxidative metabolism. Recently, 
endogenous 4-1BB activation was found to drive murine T cell oxidative metabolism by 
p38 MAPK-mediated PGC1a expression (Menk et al., 2018). PGC1a binds the TFAM 
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promoter thereby inducing its expression (Wu et al., 1999). These findings suggest that 
BBz CAR signaling may not simply be associated with oxidative metabolism, but may 
drive it directly through p38 MAPK signaling. There is at least one other explanation of 
our data that we must address. Both our experiments and those first connecting anti-
CD19 BBz CAR signaling to oxidative metabolism (Kawalekar et al., 2016) were 
performed in the presence of IL-15. IL-15 can independently drive oxidative metabolism 
in T cells (Bordon, 2012). Furthermore, T cell metabolism can be driven towards a 
glycolytic phenotype by CD28 activation (Frauwirth et al., 2002). Therefore, it is possible 
that the reported connection between anti-CD19 BBz CAR signaling and oxidative 
metabolism may be due to IL-15, the effect of which may be overcome by 28z CAR-
driven glycolytic polarization. In any case, we conclude that BBz CAR-driven ncNF-kB 
signaling is not responsible for BBz CAR-associated oxidative metabolism, and therefore 
supports anti-CD19 BBz CAR T cell survival by another mechanism. 
NcNF-kB signaling enhances survival of both myeloma cells and T cells by 
suppression of the pro-apoptotic protein, Bim (Vallabhapurapu et al., 2015; Wang et al., 
2008). Bim plays a central role in T cell survival with expression that increases with T 
cell activation, and is repressed by ERK signaling (Bouillet et al., 2002; Hildeman et al., 
2002; Masson et al., 2011; Wojciechowski et al., 2006). The latter was previously 
identified as a key mechanism by which endogenous murine 4-1BB enhances T cell 
survival (Sabbagh et al., 2008); however, ncNF-kB signaling has been implicated with 
ERK signaling in Bim regulation within multiple myeloma suggesting that these two 
pathways are not mutually exclusive (Vallabhapurapu et al., 2015). In particular, ERK 
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influences the cellular abundance of Bim in at least two ways: cooperation with RelB/p52 
dimers to inhibit Bim transcription (Vallabhapurapu et al., 2015), and through the 
phosphorylation and subsequent degradation of the BimEL isoform (Ley et al., 2005; 
Luciano et al., 2003). This latter function of ERK may explain why we did not observe 
differences in BimEL expression between anti-CD19 28z and BBz CAR T cells or 
between dnNIK expressing BBz CAR T cells relative and their controls (Figures 2.17B, 
E, 2.19A, D), given that ERK is active in both settings (Figures 2.5D-E, 2.20) (Salter et 
al., 2018). The observed increases in BimL and BimS expression in dnNIK expressing 
BBz CAR T cells relative to controls after CAR activation (Figures 2.17F-G) are 
consistent with a transcriptional effect. In addition, the BimL and BimS isoforms are even 
more potent sensitizers to apoptosis than BimEL (O'Connor et al., 1998) and are capable 
of diminishing T cell survival in the absence of BimEL (Clybouw et al., 2012). Although 
we were unable to detect a difference in BimL and BimS expression between anti-CD19 
28z and BBz CAR T cells following CAR-mediated expansion despite baseline 
differences, this may be due to selection events occurring in the 28z culture as observed 
with the early loss of cells upon bead stimulation (Figure 2.15A) and consistent with 
previous work describing rapid 28z CAR T cell effector differentiation and cell loss 
(Kawalekar et al., 2016; Salter et al., 2018). Bim suppression is an important down-
stream effect of 4-1BB-induced ncNF-kB signaling and likely contributes to BBz CAR-
mediated T cell survival, and further studies are needed to identify additional ncNF-kB 
responsive genes that may also contribute to this survival.  
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Our system has allowed us to identify non-canonical NF-kB signaling as a 
specific and critical mediator of 4-1BB co-stimulated CAR T cell survival, but we must 
also acknowledge some of its limitations. In this report, we have focused upon anti-CD19 
CARs, which our group (Carpenito et al., 2009; Milone et al., 2009), and Salter et. al 
(Ramello et al., 2019; Salter et al., 2018) have employed to study CAR signaling. Though 
it is possible that our findings regarding CAR T cell survival are limited to the anti-CD19 
CAR, 4-1BB-costimulated CAR T cells targeting multiple other antigens have been 
described as having similar enhanced survival (Guedan et al., 2018; Priceman et al., 
2018; Song et al., 2011; Wang et al., 2015). The overexpressed, dominant-negative 
mutant of NIK was chosen for our studies due to the well described effects of this 
approach in disrupting ncNF- B (Xiao et al., 2001), and the lack of commercially 
available pharmacological inhibitors (Paul et al., 2018) or efficient gene-editing 
technologies to silence expression of an intracellular protein in primary human T cells 
(Chen, 2015). Although protein overexpression and dominant negative mutants can have 
unintended, off-target effects, the absence of an appreciable impact of dnNIK expression 
on both polyclonal T cell expansion via anti-CD3/anti-CD28 beads or 28z CAR-mediated 
expansion supports the generally non-toxic and targeted nature of our approach (Figures 
2.15A-B).  
In summary, we have identified an essential and non-redundant mechanism by 
which 4-1BB costimulation within a CAR supports T cell survival: namely by mediating 
both basal and ligand-dependent activation of non-canonical NF-kB signaling, which is 
associated with reduced expression of the most pro-apoptotic isoforms of Bim.  NcNF-
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kB signaling by 4-1BB-costimulated CARs also likely influences gene expression in 
CAR T cells beyond those affecting survival and persistence, as this pathway regulates 
the expression of many genes such as chemokines and cytokines that are important for T 
cell trafficking and function (Sun, 2017).  Although not evaluated in our study, ncNF-kB 
signaling has been reported to be required for GM-CSF production by Th17 cells (Yu et 
al., 2014) suggesting that the 4-1BB-induced activation of this pathway could play a role 
in cytokine release syndrome that depends upon this cytokine (Sachdeva et al., 2019; 
Sterner et al., 2019).  Our study therefore represents only a beginning for the study of this 
unique and complex signaling pathway in CAR T cells that clearly deserves further 
exploration. 
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MATERIALS AND METHODS 
Primary Cells and Nalm6 cells 
Primary human T cells were procured and cultured as described previously 
(Milone et al., 2009). Briefly, peripheral blood mononuclear cells were collected from 
anonymous healthy donors by aphaeresis. T cells were isolated from these aphaeresis 
products by the University of Pennsylvania Human Immunology Core using Lymphoprep 
and RosetteSep human T cell Enrichment Cocktail kits (Stem Cell Technologies) per 
manufacturer’s instructions. Primary human T cells were cultured at 37°C in RPMI 1640 
media (Gibco) supplemented with 10% FBS, HEPES buffer (final concentration 10 mM), 
penicillin (100 units/mL) and streptomycin (100 µg/mL). Nalm6 cells (ATCC) were 
cultured at 37‡C in the same media as T cells, and re-fed every other day to a 
concentration of 0.25e6 cells/mL. Immediately prior to use as stimulator cells, Nalm6 
cells were irradiated with 100 Gy using an X-ray irradiator. 
Generation of high-titer lentiviral vectors and T cell transduction 
All CAR constructs used were constructed as previously described (Fig. S14) 
(Carpenito et al., 2009; Milone et al., 2009). All lentiviral vectors were produced and 
used to transduce primary human T cells for all single transduced T cell assays as 
previously described (Milone et al., 2009). Dual transduced CAR T cells were generated 
as follows. We transduced T cells with anti-CD19 CARs containing either CD28 or 4-
1BB costimulatory domains from healthy donor bulk T cells using lentiviral transduction, 
as described previously (Milone et al., 2009). These cells were subsequently transduced a 
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second time with either a control lentiviral vector expressing mCherry, or a bicistronic 
vector expressing a dominant-negative mutant of NF-kB-inducing kinase and mCherry, 
which were separated in the vector by a T2A site. These dual transduced cells were 
cultured for 5-8 days, sorted to purity on mCherry expression, and further expanded with 
IL-7 and IL-15 (Premium grade, Miltenyi Biotec, 10 ng/mL final concentration) added 
with R10 media every other day to maintain a starting concentration of .75e6 cells/mL. 
This expansion regimen was maintained until the cells plateaued in size as measured on a 
Coulter Counter (Beckman Coulter) for two consecutive measurements. These cells were 
either immediately used in assays (described as “fresh”) or cryopreserved as described 
previously (Milone et al., 2009). Cells were enumerated by combining counts collected 
on a Coulter Counted (Beckman Coulter) with viability as assessed by flow cytometry 
using 7AAD (Cell viability solution, BD Via-Probe) exclusion (Fig. S15A). CD4 
(BUV395, RPA-T4, BD Biosciences), CD8 (BV785, RPA-T8, BioLegend), and CD19 
(APC, HIB19, STEMCELL) expression were also assessed by flow cytometry. 
Elimination of irradiated Nalm6 stimulator cells by day 3 following addition was 
confirmed by the absence of CD19+ cells (Figure 2.22). 
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Preparation and use of stimulation beads 
Stimulator beads were prepared as described previously (Kawalekar et al., 2016). 
Briefly, Dynabeads M-450 Tosylactivated (Invitrogen) were washed and resuspended in 
a pH 9.5 borate buffer at 4e8/mL, incubated overnight with 150 µg of anti-CD19 idiotype 
antibody (Novartis) or mesothelin-Fc at 37°C with constant mixing. The beads were then 
washed 3 times in a wash buffer (3% human AB serum, 0.1% sodium azide, and 0.4% 
Figure 2.22: Representative gating strategy to quantify cell death by flow 
cytometry and assess CD19+ Nalm6 cell elimination. (A) T cell culture gating 
strategy shown for D14. 7AAD+ mRFP- events were counted as dead cells. 7AAD- 
mRFP- events were assessed for CD19+ expression. (B) All mCherry negative, 7AAD 
negative cells stained for CD19 prior to second round of irradiated Nalm6 addition 
(Day 7), 3 days later (Day 10), and 5 days later (Day 12). All mCherry negative, 
7AAD negative events from Nalm6-only parallel culture assessed on D14 of T cell 
culture shown for CD19 positive control. 
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0.5M EDTA in PBS) at 4°C for 10 minutes each with constant mixing, followed by an 
overnight wash at 4°C in the same buffer with constant mixing. Prior to use, beads were 
washed 3 times in PBS, and then resuspended in the same RPMI-based media as above. 
Before use in experiments, beads were QC’d by mixing with BBz CAR T cells at a 3:1 
bead-to-cell ratio. Bead activity was assessed by T cell size measured by Coulter Counter 
after 3 days compared to the same BBz CAR T cells mixed with previous batches of 
beads at the same ratio used in parallel as a positive control, and BBz CAR T cells alone 
as a negative control. Beads were then used at a 3:1 bead-to-cell ratio for all bead-based 
expansion assays, and at a 5:1 bead-to-cell ratio for all signaling assays. T cells for 
expansion assays were mixed with beads and cultured as above. T cells for stimulation 
assays were mixed with beads and spun down to synchronize bead-cell contact. They 
were then incubated at 37°C for the indicated time periods. 
Whole cell lysis 
Ripa buffer stock was made at 1X consisting of 150 mM NaCl, 1% NP-40, 0.5% 
Deoxycholate, 0.1% SDS, and 50 mM Tris at pH 8.0. The stock was stored at 4°C. The 
night before use, one tablet each of phosphatase inhibitor (PhosSTOP, Roche) and 
proteasome inhibitor (cOmplete, Roche) was added to a working volume of Ripa buffer. 
On the day of lysate collection, T cells were harvested from cell culture, washed with ice-
cold PBS (Corning), and resuspended in the working stock of ice-cold Ripa buffer. 
Lysates were incubated on ice for 30 minutes, while being vortexed at maximum for 10 
seconds at 10 minute intervals. They were then spun down at 16,000 x g for 10 minutes 
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in a refrigerated centrifuge. The supernatants were collected, aliquoted and immediately 
frozen at -80°C. 
Nuclear/Cytoplasmic fractionation 
Our nuclear/cytoplasmic fractionation technique was adapted from a previously 
described method (Madge and May, 2009). Cytoplasmic buffer stock was made at 1X 
consisting of 10 mM HEPES, 10 mM KCl, and 0.1 mM EDTA, adjusted to pH 7.9. 
Nuclear buffer stock was made at 1X consisting of 20 mM HEPES, 0.42 M NaCl, and 0.1 
mM EDTA, adjusted to pH 7.9. Both buffers were stored at 4°C. The night before use, 
one tablet each of phosphatase inhibitor (PhosSTOP, Roche) and proteasome inhibitor 
(cOmplete, Roche) was added to a working volume of each buffer. On the day of lysate 
collection, T cells were harvested from cell culture, washed with ice-cold PBS (Corning), 
and resuspended in the working stock of ice-cold cytoplasmic buffer. Samples were 
incubated on ice for 10 minutes. A final concentration of 0.1% NP-40 (ThermoFisher 
Scientific) was added to each sample. Each sample was then incubated at room 
temperature for 5 minutes, followed by a 10 second maximum speed vortex, and 
immediate centrifugation at 4000 x g for 90 seconds at 4°C. Supernatants were collected 
on ice, aliquoted, and frozen at -80°C for later use as the cytoplasmic fraction. The 
remaining nuclear pellets were washed twice with ice-cold cytoplasmic buffer, and 
transferred to a fresh tube. They were then resuspended in ice-cold nuclear buffer and 
shaken at 4°C for 30 minutes at 1400 rpm. Samples were then spun at 16,000 x g for 15 
minutes at 4°C. Supernatants were collected, aliquoted on ice, and stored at 80°C to be 
used as nuclear fractions. 
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Western Blot Analysis 
Lysates were thawed on ice, and protein concentration was assessed by DC 
Protein Assay (Bio-Rad) as per manufacturer’s instructions. Equal quantities of protein 
were added to Laemmli buffer (Bio-Rad) containing 2-mercaptoethanol (Bio-Rad) and 
boiled at 95°C for 5 minutes. Protein was separated in NuPAGE gels using the Cell 
SureLock Mini-Cell (Invitrogen) and transferred to a methanol-activated PVDF-FL 
membrane (Millipore Sigma) in the Mini Trans-Blot Electrophoretic Transfer Cell (Bio-
Rad) in 10% methanol NuPAGE transfer buffer (ThermoFisher Scientific). Following 
transfer, the membranes were incubated in methanol for 1 minute, followed by a 
deionized water wash, then incubated in TBS for 2 minutes, prior to blocking in TBS 
Odyssey blocking buffer (LI-COR) for 1 hour. Proteins were visualized using the 
following primary antibodies, incubated overnight at 4°C in TBS Odyssey blocking 
buffer (LI-COR) with 0.5% Tween 20 (Bio-Rad): PCNA (PC10, 1:2000, Cell Signaling 
Technology), Actin (8H10D10, 1:1000, Cell Signaling Technology), Phospho-Zap-70 
(Tyr319, 65E4, 1:1000, Cell Signaling Technology), Zap-70 (L1E5, 1:1000, Cell 
Signaling Technology), Phospho-p65 (Ser536, 93H1, 1:1000, Cell Signaling 
Technology), p65 (L8F6, 1:1000, Cell Signaling Technology), Phospho-p44/42 MAPK 
(ERK1/2) (Tyr202/Tyr204, D13.14.4E, 1:2000, Cell Signaling Technology), p44/42 
MAPK (ERK 1/2) (L34F12, 1:2000, Cell Signaling Technology), NIK (1:750, Cell 
Signaling Technology), Phospho-NF-kB2 p100 (Ser866/870, 1:1000, Cell Signaling 
Technology), Anti-NF-kB p52 (1:1000, Millipore Sigma), RelB (D7D7W, 1:1000, Cell 
Signaling Technology), Bim (C34C5, 1:1000, Cell Signaling Technology). Each 
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membrane was only incubated with one primary antibody from a single origin species 
(Rabbit or Mouse) at one time. The membranes were washed with TBS containing 0.1% 
Tween 20, and incubated with Donkey anti-Rabbit (IRDye 800CW, 1:15000, LI-COR) 
and/or Donkey anti-Mouse (IRDye 680RD, 1:15000, LI-COR) secondary antibodies in 
TBS Odyssey blocking buffer (LI-COR) with 0.5% Tween 20 and 0.1% SDS 
(ThermoFisher Scientific) for 40 minutes at room temperature. The membranes were then 
washed again with TBS containing 0.1% Tween 20, rinsed once in TBS, and then kept in 
TBS at 4°C until imaging. Membranes were imaged using the Odyssey CLx (LI-COR) 
and fluorescence was evaluated using Image Studio (LI-COR). When membranes were 
re-probed to visualize additional proteins, they were first re-blocked in TBS Odyssey 
blocking buffer (LI-COR) for 1 hour at room temperature, and then steps were repeated 
as above. 
Metabolic phenotype analysis 
 Mitochondrial respiration and cellular glycolytic rate were assessed using an 
XF96 extracellular flux analyzer (Seahorse Bioscience). CAR T cells were metabolically 
phenotyped prior to and 14 days after coculture with anti-CD19 idiotype antibody-coated 
beads, as described above. Analysis was conducted as described previously (Kawalekar 
et al., 2016). 
Statistical analysis 
Results are expressed as a mean +/- standard deviation. All Log FC values are 
derived as follows: Log2 of ((@ time of interest of experimental group: raw fluorescence 
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of the protein of interest/raw fluorescence of relevant loading control)/(@ control time 
point of control group: raw fluorescence of protein of interest/raw fluorescence of 
relevant loading control)). Statistical comparisons were made as listed in figure legends, 
with factors of 2-way ANOVA analyses being CAR and Time, using Prism (GraphPad). 
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CHAPTER 3 – DISCUSSION 
CAR T cell therapies are the vanguard of a new treatment paradigm in which 
patients are given medications that are “alive.” The replication and survival of CAR T 
cells following adoptive transfer is an important factor impacting patient outcomes. 
Recent research efforts have demonstrated that T cell survival is affected by the structure 
of the CAR itself, especially by the choice of costimulatory domain. At the outset of the 
work reported in this thesis, the mechanism by which the costimulatory domain within a 
CAR promotes T cell survival was unclear. Recent investigations into this question have 
highlighted the negative effect of CD28 costimulation on CAR T cell survival. Here, for 
the first time, we have demonstrated that 4-1BB costimulation directly supports CAR T 
cell survival through activation of the non-canonical NF-kB (ncNF-kB) pathway, a 
pathway that has never before been observed downstream of 4-1BB signaling in human 
cells. We have also identified ncNF-kB-mediated Bim suppression as a possible 
mechanism by which 4-1BB costimulation supports CAR T cell survival. As CAR T 
cells, and other T cell-based therapies, are developed to treat other cancers and non-
malignant diseases, understanding the mechanisms impacting CAR T cell survival will be 
critical in optimizing them to achieve the most durable outcomes for patients. 
NOVELTY AND IMPLICATIONS 
 This work is the first to demonstrate that the 4-1BB intracellular domain of a 
second generation CAR directly enhances CAR T cell survival. To date, studies had 
associated 4-1BB with CAR T cell survival, and CD28 with early CAR T cell death 
(Kawalekar et al., 2016; Long et al., 2015; Majzner and Mackall, 2019; Milone et al., 
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2009; Salter et al., 2018; Wang et al., 2015). However, these studies had only shown that 
CD28 costimulation exerts a negative effect, likely due to greater phosphorylation of 
downstream signaling targets and constitutive association with Lck (Feucht et al., 2019; 
Long et al., 2015; Salter et al., 2018). This conclusion did not explain how 4-1BB 
costimulation enhanced their expansion and persistence (Drent et al., 2019; Zhao et al., 
2015). Our work now demonstrates a direct contribution by the 4-1BB intracellular 
domain to CAR T cell survival and identifies a mechanism by which it achieves this 
enhanced survival: ncNF-kB signaling. 
 Our report is the first observation of 4-1BB-mediated non-canonical NF-kB 
signaling in human T cells, and is consistent with previous data demonstrating non-
canonical NF-kB signaling downstream of endogenous murine 4-1BB (McPherson et al., 
2012), but not downstream of CD28 (Li et al., 2005; Marinari et al., 2004). Additionally, 
our study is the first to distinguish non-canonical from canonical NF-kB signaling 
downstream of second generation CARs. Multiple reports provide conflicting data on the 
role of canonical NF-kB signaling in the survival of second generation CAR T cells 
(Carpenito et al., 2009; Li et al., 2018). By identifying ncNF-kB signaling as a 
downstream mediator of BBz, but not 28z, CAR T cell survival, we have identified a 
potentially “druggable target” to enhance the survival of non-4-1BB costimulated T cells 
(Tchoghandjian et al., 2013).  
 Finally, we identify Bim as a novel potential regulator of CAR T cell survival. 
Our data showing that 4-1BB-mediated ncNF-kB signaling suppresses Bim is consistent 
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with previous reports that endogenous murine 4-1BB suppresses Bim (Sabbagh et al., 
2008), likely by cooperative action of ERK and ncNF-kB signaling (Sabbagh et al., 2008; 
Vallabhapurapu et al., 2015; Wang et al., 2008). Furthermore, Bim regulates T cell 
survival in vivo (Bouillet et al., 2002; Gibbons et al., 2012; Hildeman et al., 2002; Wang 
et al., 2008; Wojciechowski et al., 2006; Zhu et al., 2004), supporting our hypothesis that 
4-1BB-mediated ncNF-kB signaling enhances CAR T cell survival by suppressing Bim. 
LIMITATIONS 
Although we believe our findings are exciting and have important implications, 
our study also has limitations and raises many new questions;  In the spirit of self-
critique, some of these will be discussed in detail below. 
One limitation of our work is that we did not demonstrate that BBz CARs directly 
activate ncNF-kB signaling. A possible alternative interpretation of our data is that BBz 
CARs induce more expression of OX40 and OX40L than do 28z or first generation 
CARs, which may be responsible for the ncNF-kB signaling that we observed (Kondo et 
al., 2007; Soroosh et al., 2006; Xiao et al., 2012). Although this indirect signaling is 
possible, OX40 and OX40L tend to be expressed with even more delayed kinetics  
(Soroosh et al., 2006; Takasawa et al., 2001) and would not be consistent with the more 
rapid stabilization of NIK that we observed in our system (Figures 2.6A-B). Specifically, 
OX40-OX40L-mediated NIK stabilization and downstream ncNF-kB signaling would 
not be expected  to be detectable for at least a day following CAR activation. Instead, we 
observe NIK stabilization as early as 2-4 hours after receptor activation (Figures 2.6A-B) 
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and peak signaling either at 12 hours in anti-CD19 BBz CAR T cells (Figures 2.6A-B). 
Furthermore, TCR activation through canonical NF-kB signaling induces expression of 
OX40 and OX40L (Tone et al., 2007). Yet, we see similar levels of canonical NF-kB 
signaling downstream of both 28z and BBz anti-CD19 CARs (Figures 2.5A, C), but less 
ncNF-kB signaling from both anti-CD19 and SS1 28z CARs compared to BBz CARs 
with the same scFv’s (Figures 2.7-10). Given our findings, and that murine 4-1BB has 
been observed to activate ncNF-kB (McPherson et al., 2012), it seems most likely that 
the 4-1BB costimulatory domain directly activates ncNF-kB signaling. 
Another issue is that although our bead-based CAR activation system allowed us 
to study signaling specifically activated by CARs, it was not a high-fidelity model for 
anti-CD19 CD28 CAR T cell expansion (Neelapu et al., 2017). We believe that there are 
at least two factors underpinning this limitation. First, Nalm6 cells and other ALL cells 
targeted by anti-CD19 CAR T cells express integrin receptor ICAM3 and have the 
capacity to express CD28 ligands CD80 and CD86 upon co-culture with activated T cells 
(Li et al., 2013). All of these molecules provide additional costimulatory signals not 
present on the beads (Juan et al., 1994; Lenschow et al., 1996). Second, target cells 
provide a transient stimulus that diminishes as they are killed by CAR T cells. In contrast, 
the anti-CD19 idiotype beads provide a continuous signal to CAR T cells, which has been 
shown to be detrimental particularly to CD28-costimulated CAR T cells (Long et al., 
2015). These differences are somewhat advantageous to our efforts to isolate a survival 
signal triggered by the CAR. The lack of additional costimulatory signals allows for the 
isolation of the CAR signal itself, and the continuous antigen interactions with the CAR 
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increase our ability to detect subsequent downstream signaling. It is possible that the 
diminished expansion and survival of anti-CD19 28z CAR T cells in the bead system 
may mask dnNIK-mediated toxicity, but the cell death observed with the anti-CD19 28z 
CAR T cells is incomplete (Figure 2.15A). We therefore should still be able to detect an 
increase in cell death if dnNIK was non-specifically toxic. Additionally, dnNIK-
expressing T cells, regardless of CAR, expand identically to their control counterparts in 
primary cultures. This similarity strongly argues against non-specific toxicity of dnNIK-
expression and supports the validity of our conclusions from the bead-based expansion 
assays. 
Finally, we were also unable to directly demonstrate ncNF-kB signaling-mediated 
transcriptional regulation of Bim. We did attempt to do so by qPCR. However, the qPCR 
primers available were not specific to each Bim isoform, and yielded conflicting results 
in two attempts. Given this limitation, it was difficult to reconcile that data with our 
protein expression data. Additionally, assessing RelB/p52 bcl2l11 locus binding was 
technically challenging. Previous investigators have done so by ChIPseq, or ChIP-qPCR 
(Vallabhapurapu et al., 2015), but this technique measures the amount of DNA bound to 
either RelB or p52, and not how much RelB or p52 binds the bcl2l11 locus. Furthermore, 
assessing where this dimer is bound is difficult because we would need to assess overlap 
in binding of each monomer separately, and the antibodies to RelB are suboptimal. 
Although we cannot exclude that ncNF-kB signaling impacts BimL and BimS expression 
by some as yet undescribed post-translational mechanism, our findings are consistent 
with the previously described transcriptional suppression of Bim mediated by ncNF-kB 
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signaling (Vallabhapurapu et al., 2015) and ncNF-kB-mediated Bim suppression 
enhancing T cell survival (Wang et al., 2008). 
OUTSTANDING QUESTIONS 
Having demonstrated that 4-1BB directly promotes CAR T cell survival, we 
would have expected that adding the 4-1BB intracellular domain to a 28z CAR should 
enhance the survival of a T cell expressing such a CAR. However, these “third 
generation” CAR T cells have been largely equally or less effective than their second 
generation counterparts (Carpenito et al., 2009; Majzner and Mackall, 2019; Milone et 
al., 2009). This outcome is likely due to a structural limitation of these CARs. When 
added in cis, in the same molecule as the CD28 domain and the z-chain, the 
costimulatory domain distal to the plasma membrane does not seem to function (Guedan 
et al., 2018; Ramello et al., 2019). CARs with the 4-1BB domain distal to the membrane 
do not appear to associate with TRAF molecules (Ramello et al., 2019), preventing them 
from transmitting a signal (Zapata et al., 2018). However, this strategy also results in 
distancing the zeta chain from the CD28 domain, which may reduce the ability of Lck to 
phosphorylate the CAR’s ITAMs (Feucht et al., 2019; Zhao et al., 2009). This reduction 
may moderate the detrimental tonic signaling and enhanced phosphorylation cascades of 
the CD28 domain of the CAR (Feucht et al., 2019; Ramello et al., 2019; Salter et al., 
2018), which might explain the superior performance of the 3rd generation CAR to the 
28z CAR in a single small clinical trial (Ramos et al., 2018). Yet, these findings together 
suggest that the 4-1BB domain when incorporated into a third generation CARs does not 
directly enhance CAR T cell persistence. 
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Even when added in trans, as achieved by co-expression of 4-1BBL in CD28 
costimulated CAR T cells (Drent et al., 2019; Zhao et al., 2015), 4-1BB-mediated 
survival may be mostly overshadowed by CD28 costimulated CAR-induced exhaustion 
(Long et al., 2015) or AICD (Feucht et al., 2019). Furthermore, this strategy will only 
cause 4-1BB activation while endogenous 4-1BB is expressed. Endogenous 4-1BB is not 
expressed on resting T cells, and its expression peaks within days of T cell activation 
(Pollok et al., 1993). 4-1BBL-expressing anti-CD19 28z CAR T cells rarely survive to 
160 days in patients (Batlevi et al., 2019), which may be explained by our data suggesting 
that constitutive ncNF-kB signaling may be critical for long-term CAR T cell persistence. 
Interestingly, we observed constitutive ncNF-kB signaling in T cells expressing BBz 
CARs with two different scFvs and antigen specificities (Figures 2.7-10), yet, in anti-
CD19 BBz CAR T cells, ERK is only phosphorylated upon CAR-ligand binding (Figures 
2.5A, D-E). How can a single receptor activate one pathway constitutively, but another 
only upon ligand binding?  
CARs have been shown to signal in the absence of antigen, which can be 
mediated by scFv-dependent CAR clustering (Long et al., 2015). The FMC63 scFv 
targeting CD19 causes small punctate clusters distributed across the T cell plasma 
membrane, and a more basally active CAR with a GD2-targeting scFv forms even larger 
clusters that are not evenly distributed (Long et al., 2015). As SS1-scFv-containing CARs 
targeting mesothelin also signal in the absence of antigen (Frigault et al., 2015), they 
likely also form higher-order clusters. In both CARs used here, these clusters may 
facilitate 4-1BB costimulatory domain activation, meditated by recruitment of TRAF1 
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and TRAF2. TRAF2 recruitment to crosslinked TNFRSFs retargets the E3 ubiquitin 
ligases cIAP1 and cIAP2 to TRAF3, which enables the stabilization of NIK and 
subsequent ncNF-kB signaling (Luftig et al., 2004; Vallabhapurapu et al., 2008). 
Clustering of 4-1BB costimulated second generation CARs may mimic crosslinking of 
other related TNFRSFs, thereby facilitating ncNF-kB signaling in the absence of antigen. 
Unlike 4-1BB-mediated ncNF-kB signaling, TRAF-binding alone is insufficient 
for 4-1BB-mediated ERK activation. 4-1BB activates ERK by coordinating both TRAF1 
and Leukocyte Specific Protein 1 (LSP1) (Sabbagh et al., 2013). LSP1 is associated with 
the intracellular plane of the plasma membrane in resting T cells (Matsumoto et al., 
1995). Upon TCR activation, ZAP-70 activates PKCq, which rapidly phosphorylates 
LSP1 causing it to dissociate from the membrane (Matsumoto et al., 1995). Once in the 
cytosol, LSP1 can activate ERK (Wu et al., 2016). As BBz CARs do not induce ZAP-70 
phosphorylation and downstream PKCq activation in the absence of antigen (Salter et al., 
2018), LSP1 is likely unphosphorylated, membrane-bound, and unable to interact with 
TRAF1. Upon antigen binding, BBz CARs activate ZAP-70, which would enable PKCq 
phosphorylation of LSP1. Phospho-LSP1 would then be released into the cytosol, where 
it could bind TRAF1 and activate ERK. This model combined with scFv-mediated 
clustering suggests how BBz CARs could differentially regulate ERK and ncNF-kB 
signaling. 
Whereas the 4-1BB domain within the CAR may not initiate the same signals as 
the endogenous 4-1BB in the absence of CD3z signaling, 4-1BB costimulated CARs do 
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seem to initiate downstream signaling similarly to the endogenous 4-1BB. The 4-1BB 
domain in CARs is only capable of initiating signaling and drive clonal expansion when 
it can associate with TRAFs 1 and 2 (Li et al., 2018; Mamonkin et al., 2017), as is the 
case for endogenous 4-1BB (Zapata et al., 2018). Upon ligand binding and TRAF2 
association, endogenous 4-1BB is internalized into K63-ubiquitin-associated vesicles 
(Martinez-Forero et al., 2013). Intriguingly, 4-1BB costimulated CARs also rapidly 
internalize upon ligand binding and also remain stably associated with their ligand within 
these vesicles (Hamieh et al., 2019). Though we did not directly observe or test whether 
CAR internalization was required for 4-1BB-mediated non-canonical NF-kB signaling, 
we hypothesize from the observations cited here and the similar constellations of 
signaling pathways that we observed downstream of the 19BBz CAR compared to those 
downstream of endogenous 4-1BB that 4-1BB costimulated CARs utilize the same 
intracellular mechanisms to initiate downstream signaling as endogenous 4-1BB. 
ERK and ncNF-kB signaling can cooperatively suppress Bim transcription 
(Vallabhapurapu et al., 2015), so it was somewhat surprising to observe differential 
regulation of the three Bim isoforms in our studies. CAR T cell expression of BimEL, the 
longest and least pro-apoptotic isoform, is regulated differently than its shorter splice 
variants, BimL and BimS (Figures 2.17-19). One possible mechanism by which BimEL 
protein expression may be decoupled from that of BimL and BimS is highlighted in 
Chapter 2: ERK-mediated degradation through binding the DEF-type domain only found 
in BimEL (Clybouw et al., 2012; Ley et al., 2005; 2004; Luciano et al., 2003). 
Alternatively, the three Bim isoforms are known to differ in their protein expression via 
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the stabilization of BimEL and BimL isoforms by association with the cytoskeleton. BimEL 
and BimL contain a dynein light chain binding domain that is spliced out of the Bims 
isoform (Puthalakath et al., 1999). This association appears to stabilize these isoforms as 
well as prevent them from interacting with anti-apoptotic proteins on the surface of 
mitochondria (Puthalakath et al., 1999). Though this may be a mechanism by which 
BimEL and BimL may be stabilized while BimS is degraded in other cell types, our data 
does not reflect a decoupling in protein expression between BimL and BimS as would be 
expected if the inclusion of the dynein light chain binding domain stabilized Bim 
(Figures 2.17, 19). Furthermore, our findings are consistent with previous reports that 
BimEL and BimL are not exclusively sequestered to the cytoskeleton in T cells (Zhu et al., 
2004), and that BimEL association with the cytoskeleton does not shield it from ERK-
mediated degradation (Mouhamad et al., 2004). 
Though BimEL expression does not appear to be associated with ncNF-kB 
signaling at any time point in CAR T cells, we were somewhat surprised that BimL and 
BimS expression only increased in dnNIK-expressing anti-CD19 BBz CAR T cells 
relative to their controls following CAR activation (Figures 2.17F-G). Having observed 
BBz CAR-mediated tonic ncNF-kB signaling, we anticipated that Bim expression would 
be increased prior to activation in dnNIK-expressing BBz CAR T cells as well. One 
possible explanation is that dnNIK expression in our system may not have sufficiently 
blocked basal ncNF-kB signaling to achieve a measurable reduction in Bim. The 
blockade we achieve is incomplete at all timepoints, but is least consistently detectable 
prior to 4-1BB costimulated CAR activation (Fig. 2.13). Therefore, dnNIK-expressing 
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BBz CAR T cells may still have enough ncNF-kB signaling to mediate a similar degree 
of Bim suppression as the control BBz CAR T cells. 
A final puzzling finding regarding Bim regulation was that we only detected a 
difference in BimL and BimS expression between 28z and BBz CAR T cells before CAR 
activation (Fig. 2.19). One interpretation of this finding is that BimL and BimS expression 
may not contribute to the difference in 28z and BBz CAR T cell survival following CAR 
activation. However, we believe that there is an alternative explanation for this 
observation in line with our hypothesis. It is possible that CD28 costimulated CAR T 
cells cannot tolerate higher expression of Bim. Bim induces cell death by blocking 
activity of anti-apoptotic Bcl-2-family proteins (O'Connor et al., 1998), but can also 
bypass the Bcl-2-family-regulated intrinsic apoptosis pathway by interacting with Bid to 
augment Fas-FasL-mediated apoptosis (Masson et al., 2011). Fas is expressed following 
T cell activation during CAR T cell production (Ghassemi et al., 2018), and FasL 
expression is dramatically increased by CD28-costimulated CAR activation relative to 
BBz CAR activation (Feucht et al., 2019; Künkele et al., 2015). Therefore, 28z CAR T 
cells may require less Bim than  BBz CAR T cells to cause cell death following CAR 
activation. 
Increased Bim expression in the context of dnNIK inhibition of ncNF-kB 
signaling could explain the dramatic loss of expansion of dnNIK-expressing anti-CD19 
BBz CAR T cells, but, as Bim promotes apoptosis, we were somewhat surprised by the 
small magnitude of the increase in cell death (Figure 2.14A-C). DnNIK-expressing anti-
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CD19 4-1BB costimulated CAR T cells expanded 10 fold less than their control 
counterparts (Fig. 2.14B), but only experienced a 6% increase in cell death (Fig. 2.14C). 
Though the increase in dying cells is modest, we interpret this measure as an 
“instantaneous rate” of cell death. We report dead cells as those that have lost membrane 
integrity (by losing mCherry), but retain some DNA (7AAD+). These dying cells then 
become debris over the course of the culture, becoming 7AAD- and falling out of the 
dead cell gate. It is likely that the increased death rate has cumulative effect on 
expansion, where small increases over long periods of time result in a large loss of 
expansion. 
Another contribution to the loss of expansion of dnNIK-expressing anti-CD19 
BBz CAR T cells could be due to a reduction in cell cycle progression. There is a small 
reduction in PCNA expression in dnNIK-expressing anti-CD19 BBz CAR T cells that did 
not reach statistical significance (Fig. 2.14D), potentially reflecting that a smaller fraction 
of cells are beyond the G1-phase of the cell cycle (Kurki et al., 1986). This reduction in 
proliferation could be due to loss of ncNF-kB-mediated promotion of cell cycle 
progression into S phase, a function of ncNF-kB signaling observed in multiple cancer 
types (Ge et al., 2016; Uno et al., 2014). Though a reduction in proliferation could 
contribute to the overall diminished expansion of dnNIK-expressing BBz CAR T cells, 
this reduction was not as large or consistent as the increase in cell death in these cells or 
in the referenced cancer lines. These data suggest that reduced ncNF-kB signaling 
diminishes expansion primarily by increasing the frequency of cell death. 
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These observations of potential downstream effectors of ncNF-kB-driven survival 
highlight the need for further investigation into ncNF-kB-mediated transcriptional 
regulation. Given previous reports that RelB/p52 dimers suppress gene transcription by 
chromatin remodeling (Vallabhapurapu et al., 2015), future investigations into the 
transcriptional impact of non-canonical NF-kB signaling in human T cells should include 
not only RNAseq and ChIPseq (if specific antibodies can be employed), but also 
ATACseq. Combining these three approaches could identify not only which genes 
RelB/p52 dimers regulate, but also reveal how the chromatin around those genes changes 
upon non-canonical NF-kB pathway activation. These hits should then be validated for 
their physiological impact. Non-canonical NF-kB signaling impacts multiple cell 
functions including cell cycle progression (Ge et al., 2016; Uno et al., 2014), migration 
(Das et al., 2018; Duran et al., 2016; Jung et al., 2016; Tchoghandjian et al., 2013), 
chemokine production (Bonizzi et al., 2004; Valiño-Rivas et al., 2016; Yang et al., 2018), 
and regulatory T cell differentiation (Grinberg-Bleyer et al., 2018; Ishimaru et al., 2006; 
Murray et al., 2011), none of which are well understood on a transcriptional level in 
human T cells. 
Based on analyses of ncNF-kB-mediated gene regulation in other cell types, we 
had hypothesized that ncNF-kB signaling drives BBz CAR-associated oxidative 
metabolism (Bakkar et al., 2012; Kawalekar et al., 2016; Zeng et al., 2015). We were 
surprised that reducing ncNF-kB signaling did not impact anti-CD19 BBz CAR T cell 
metabolism (Fig. 2.16). Recently, a study identified p38 MAPK activation of PGC1a 
expression as the driver of murine 4-1BB-mediated mitochondrial biogenesis and 
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oxidative metabolism (Menk et al., 2018). This finding suggests that BBz CAR signaling 
may directly drive BBz CAR T cell oxidative metabolism by this mechanism. However, 
oxidative metabolism was associated with human 4-1BB CAR costimulation in the 
presence of IL-15 (Kawalekar et al., 2016), which itself drives oxidative metabolism in T 
cells (van der Windt et al., 2012). Furthermore, CD28 costimulation imparts its own 
metabolic phenotype, driving down oxidative metabolism and enhancing glycolysis 
(Frauwirth et al., 2002). Future work to identify the drivers of CAR T cell oxidative 
metabolism should isolate CAR signals from exogenous cytokines to deconvolute this 
phenomenon. 
FUTURE DIRECTIONS 
The data presented here not only adds to the current understanding of how CAR T 
cell signaling impacts their survival, but also elicits questions to be investigated in future 
studies. We demonstrated that non-canonical NF-kB signaling is necessary for CD19 
BBz CAR T cell survival, but further work is necessary to determine if it is sufficient to 
enhance CAR T cell survival. Our work also suggests that tonic ncNF-kB signaling may 
be sufficient or even ideal to sustain CAR T cell survival, but future investigations will 
need to optimize the regulation of ncNF-kB signaling to maximize CAR T cell survival. 
Both of these lines of inquiry might be accomplished by activation of ncNF-kB signaling 
by an alternative approach.  
One such approach to achieving tonic ncNF-kB signaling is through treatment 
with SMAC mimetics, which stabilize NIK by causing the degradation of cIAP1 and 
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cIAP2 (Tchoghandjian et al., 2013). Interestingly, this approach has been explored 
preclinically in the context of CAR T cell therapy with a focus on using the SMAC 
mimetic to downmodulate cIAP expression in the target cells to potentiate their killing by 
T cell-secreted TNF-a (Michie et al., 2019). This study did not examine the potential 
beneficial effects of SMAC mimetic on T cell survival, which might also have been 
enhanced. Another strategy to study the effect of tonic ncNF-kB signaling alone might be 
to transduce T cells with proteins that would constitutively activate the pathway, such as 
an autonomously clustering transmembrane protein containing only the 4-1BB 
intracellular domain or a constitutively active, non-degradable NIK mutant (Liu et al., 
2012; Xiu et al., 2018). Both the pharmacologic and genetic approaches should be 
pursued in the context of either an ICOS or “tuned” CD28 CAR, so as to diminish the 
toxic effects of tonic or excessive ITAM-mediated signaling. Combining one of these 
CARs with ncNF-kB signaling may also be a useful translational strategy to improve 
activity against tumors that can down-regulate the CAR-targeted antigen or create an 
immunosuppressive environment, as  these CAR T cells are more sensitive to low antigen 
density  and less sensitive to T regulatory cell-mediated suppression than the BBz CAR 
alone (Golumba-Nagy et al., 2018; Majzner et al., 2018; Priceman et al., 2018; Walker et 
al., 2017). These CAR T cells, augmented by ncNF-kB signaling, could both resist these 
suppressive features while also potentially resisting cell death. 
If Bim suppression represents the final “common” pathway to achieve survival in 
BBz CAR T cells, another approach to enhance CAR T cell survival might be to suppress 
BimL and BimS expression. Such work would clarify whether BimL and BimS expression 
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causes CAR T cell death, or is merely inversely associated with survival. However, 
complete Bim knockout may not be a fruitful strategy, as loss of Bim allows Bcl-2 to 
block IP3R-mediated calcium release, thereby blunting T cell activation (Ludwinski et al., 
2009). One strategy to avoid this Bcl-2 dysregulation would be to replace the existing 
bcl2l11 gene with a modified bcl2l11 sequence that cannot be spliced into its smaller 
isoforms. Given that BimEL is repressed by ERK (Clybouw et al., 2012; Ley et al., 2004), 
such a strategy could maintain diminished Bim levels after CAR activation, but avoid 
aberrant Bcl-2-mediated IP3R blockade. This combination may be sufficient to maintain 
CAR T cell activation, while enhancing survival. 
How can we incorporate these data into optimizing future CAR designs? CARs 
need to be optimized for each application. For example, years-long CAR T cell 
persistence appears to be critical for durable remission in pediatric ALL, but curiously, 
not for diffuse large B cell lymphoma (DLBCL) (Majzner and Mackall, 2019). This 
difference may be due to the high rate of cancer stem cells found among ALL cells (Rehe 
et al., 2013), whereas DLBCL appears to have relatively few, if any (Husby and 
Grønbæk, 2017). Sustained control of tumors supported by a cancer stem cell population 
may require persistent CAR T cells, the creation of which may be aided by minimizing 
ITAM-mediated signaling and adding ncNF-kB signaling. 
With CARs now targeting autoreactive B cells (Ellebrecht et al., 2016), 
optimizing them for non-malignant diseases may require a contrary approach: selection 
for short-lived CAR T cells. Diseases such as pemphigus vulgaris are caused by the 
production of autoreactive antibodies, in this case, targeting desmoglein 3 (Payne et al., 
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2004). Unlike malignant B cells, these cells are not transformed and do not proliferate 
indefinitely (Hammers et al., 2015). Therefore, eliminating them is unlikely to require a 
persistent CAR T cell population. Furthermore, CAR T cells are not without the capacity 
to cause toxicity themselves (Davila et al., 2014; Morgan et al., 2013; Smith and Venella, 
2017; Sterner et al., 2019), so optimizing them to be effective and short-lived in cases 
like this could be ideal. 
MODEL 
Our findings inform an updated model explaining the association between 4-1BB 
costimulation and CAR T cell survival. 4-1BB drives less or equal phosphorylation of a 
number of downstream signaling targets compared to CD28 (Salter et al., 2018), which 
likely potentiates CAR T cell death through FAS-FASL interactions (Feucht et al., 2019; 
Künkele et al., 2015). We observed that 4-1BB also directly enhances CAR T cell 
survival by activation of non-canonical NF-kB signaling, both basally and, in the case of 
the anti-CD19 CAR, upon ligand binding. This enhancement in survival was associated 
with a decrease in expression of the most pro-apoptotic isoforms of Bim, the expression 
of which is likely restricted by RelB/p52 dimer-mediated HDAC4 recruitment to the 
bcl2l11 locus (Vallabhapurapu et al., 2015). HDAC4 deacetylates the histones bound to 
the bcl2l11 locus, thereby rendering the locus inaccessible to RNA polymerase 
(Vallabhapurapu et al., 2015). Bim expression may be further suppressed upon CAR 
ligand binding, which activates ERK1/2. ERK1 can phosphorylate RelB in cells with 
active ncNF-kB signaling, thereby enhancing HDAC4 recruitment and ncNF-kB-
mediated Bim suppression (Vallabhapurapu et al., 2015). NcNF-kB signaling may also 
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impact CAR T cell survival by suppressing the expression of other pro-apoptotic genes, 
such as BMF (Vallabhapurapu et al., 2015), and influence CAR T cell function by direct 
interaction of NIK with mitochondria (Jung et al., 2016). NIK, independently of 
downstream ncNF-kB, directly binds to mitochondria, thereby driving mitochondria to 
the cell periphery. This change in mitochondrial localization enhances tumor cell 
invasion into surrounding tissues (Jung et al., 2016). Therefore, ncNF-kB signaling not 
only enhances 4-1BB-costimulated CAR T cell survival, but may also contribute to the 
trafficking of these CAR T cells into sites containing CAR antigen. In addition to 
describing a new mechanism of 4-1BB-mediated CAR T cell survival, the work 
presented here has opened numerous avenues for further study to refine and improve our 
understanding of CAR T cell biology and the ncNF-kB pathway.  
The work presented in this thesis and many of the future directions stemming 
from it employ chimeric antigen receptors as tools to study T cell biology, as did those 
who created the first CARs. Since their invention, CARs have brought about a paradigm 
shift in therapeutic development. CAR T cell therapies have not only achieved dramatic 
results for patients for whom no further intervention existed, but have also highlighted the 
need for an even deeper understanding of T cell biology in the instances where CAR T 
cells have failed. These failures inspired this return to the bench, where CARs were first 
created. Our hope is that this work informs the enhancement of future T cell therapies, 
thereby continuing the iterative cycle of therapeutic development: from bench to bedside, 
and back again. 
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